Worldwide Healthcare Trust PLC - Annual Financial Report
(the “Company”)
Annual Financial Report for the year ended
The statements below are extracted from the Company’s annual report for the year ended
The Annual Report will be submitted to the
The Annual General Meeting will be held on Wednesday,
COMPANY PERFORMANCE
HISTORIC PERFORMANCE
FOR THE YEARS ENDED 31 MARCH
2019 2020 2021 2022 2023 2024 Net asset value per share (total 13.7% 6.5% 30.0% (5.8)% (0.1)% 12.0% return)*^ Benchmark (total return)* 21.1% 5.7% 16.0% 20.4% 2.5% 10.9% Net asset value per share 272.3p 286.9p 370.3p 346.5p 343.5p 381.1p Share price 273.0p 292.0p 369.5p 327.5p 311.5p 335.0p Premium/(discount) of share price to net asset value per share 0.3% 1.8% (0.2)% (5.5)% (9.3)% (12.1)% Dividends per share 2.65p 2.5p 2.2p 2.7p 3.1p 2.8p Leverage 4.9% 12.0% 7.6% 10.9% 10.5% 10.8% Ongoing charges^ 0.9% 0.9% 0.9% 0.9% 0.8% 0.9% Ongoing charges (including performance 1.1% 0.9% 0.9% 1.4% 0.8% 0.9% fees paid or crystallised during the year)^
Comparative periods have been restated for the sub-division of each share of 25p each into 10 new shares of 2.5p each, approved at the AGM held on
* Source: Morningstar
^ Alternative Performance Measure (see Glossary).
* Source: Morningstar
STATEMENT FROM THE CHAIR
INVESTMENT PERFORMANCE
I am pleased to present your Company’s Annual Report and Financial Statements for the year ended
Stock market volatility continued in the year under review, with company and healthcare industry fundamentals often taking a back seat to macroeconomic forces and geopolitical events. The first half of the year was dominated by investor uncertainty and concerns regarding lingering inflation and continued high interest rates. The second half of the year saw these concerns abate, which helped markets to rise, in some cases, back to all-time highs.
Against this backdrop, I am pleased to report that the Company performed well, with a net asset value per share total return of +12.0% (2023: -0.1%), outperforming the Company’s Benchmark, the MSCI World Health Care Index measured on a net total return, sterling adjusted basis, which returned +10.9% (2023: +2.5%).
The Company’s share price total return during the year was +8.6% (2023: -4.1%). The disparity between the performance of the Company’s net asset value per share and its share price was reflected in the widening of our share price discount to our net asset value per share from 9.3% at
Principal contributors to our outperformance were Big Pharma,
While the Company has underperformed the Benchmark on a five-year view (+45.8% compared to +68.3%), our long-term performance continues to be strong. From the Company’s inception in 1995 to
Further information on the healthcare sector, the Company’s investments and performance during the year can be found in the Portfolio Manager’s Review.
CAPITAL
Since the beginning of 2022, and for a variety of reasons, share price discounts across the investment company sector in the
It is the Board’s policy to buy back our shares if the Company’s share price discount to the net asset value per share exceeds 6% on an ongoing basis. Shareholders should note, however, that it remains possible for the discount to be greater than 6% for extended periods of time, particularly when sentiment towards the Company, the sector and to investment trusts generally remains poor. In such an environment, buybacks may prove unable to prevent the discount from widening. However, they enhance the net asset value per share for remaining shareholders and go some way to dampening discount volatility, which can adversely affect investors’ risk adjusted returns.
Over the year, the Company remained committed to its share buyback and issuance policy, regularly repurchasing shares. This commitment was demonstrated by the fact that a total of 80,265,298 shares were repurchased for treasury at a cost of £253m and at an average discount of 10.5%. In addition to increasing the Company’s net asset value per share, during the period under review this activity made the Company the most active acquirer of its own shares both in its sector and across the investment trust sector as a whole.
* Source: Winterflood Investment Trusts
The shares repurchased during the year under review equated to 12.8% of the Company’s share capital at the beginning of the year. The total number of shares shown to have been repurchased during the year has been adjusted to reflect the share split of each of the Company’s shares of 25p each into 10 shares of 2.5p each which took effect from
On
In a change to the Company’s stated policy, I confirm that all shares held in treasury at the date of the Company’s Annual General Meeting to be held on
REVENUE AND DIVIDEND
Shareholders will be aware that it remains the Company’s investment policy to pursue capital growth for shareholders and to pay dividends at least to the extent required to maintain investment trust status. Therefore, the level of dividends declared can go down as well as up. An unchanged interim dividend of 0.7p per share for the year ended
The Company’s net revenue for the year as a whole decreased to £16.1m from £19.7m. This was due largely to a decrease in exposure to higher yielding stocks in the portfolio as well as a reduction in the size of the portfolio due to shares bought back by the Company during the year. As a result, the revenue return per share was 2.7p (2023: 3.0p per share).
Accordingly, the Board is proposing a slightly reduced final dividend for the year of 2.1p per share (2023:2.4p per share). Together with the interim dividend already paid, this makes a total dividend for the year of 2.8p per share (2023: 3.1p per share).
The effect of share buybacks means that the reported dividend per share, which is based on the number of shares in issue at the end of the financial year, is higher than the reported revenue return per share, which is based on the average number of shares in issue over the year.
Based on the closing mid-market share price of 353.5p on
The final dividend will be payable, subject to shareholder approval, on
The Company’s dividend policy will be proposed for approval at the forthcoming Annual General Meeting.
BOARD OF DIRECTORS
Humphrey has served on the Board since 2016 and was the Chair of the
ENVIRONMENTAL, SOCIAL AND GOVERNANCE (“ESG”) MATTERS
ESG matters continue to be an important priority for the Board. Our objective is to have full, transparent disclosure on the topic. Our Senior Independent Director,
Our Portfolio Manager remains committed to taking a leading role in the development of meaningful ESG engagement practices in the healthcare sector. As part of this, they facilitate dialogue and an exchange of leading practices among investors, companies and other relevant experts on ESG, in particular, the large capitalisation pharmaceutical sector. They also engage with a broad range of companies on a regular basis where areas of improvement can be identified. Further information on both ESG matters and climate change can be found in the Portfolio Manager’s ESG report.
CONTINUATION VOTE
The Board has committed to undertaking a continuation vote every five years, with a resolution tabled at the Annual General Meeting falling in the fifth year. Accordingly, such a resolution is included in the notice of Annual General Meeting contained within this report.
In the light of the Company’s long-term track record of outperformance, the positive outlook for the healthcare sector globally and the Company’s unique ability to provide shareholders with access to a broad range of healthcare investment opportunities worldwide, the Board unanimously recommends that shareholders vote in favour of the resolution allowing the Company to continue as an investment trust for a further five years.
ANNUAL GENERAL MEETING (“AGM”)
The Company’s AGM will again be held at Saddlers’ Hall,
For those investors
I encourage all shareholders to exercise their right to vote at the AGM and to register your votes online in advance of the meeting. Registering your vote in advance will not restrict you from attending and voting at the meeting in person should you wish to do so. The votes on the resolutions to be proposed at the AGM will again be conducted on a poll. The results of the proxy votes will be published following the conclusion of the AGM by way of a stock exchange announcement and will also be able to be viewed on the Company’s website at www.worldwidewh.com.
OUTLOOK
While stock market volatility is to be expected, and in the coming year may be influenced by elections in the US and
OrbiMed further believes that the challenging investment backdrop for healthcare stocks that had existed since the easing of the COVID pandemic appears to be changing and that the recent upturn in share prices across the industry is more representative of its positive fundamentals.
Lastly, OrbiMed expects the currently high level of merger and acquisition activity in the healthcare sector to continue, supported by attractive valuations, healthy balance sheets and, within the pharmaceutical sector, a need to address future patent expirations.
Your Board shares OrbiMed’s optimism. We believe the prospects for the global healthcare sector are strong and that your Company is uniquely placed to take advantage of opportunities in a wide variety of companies around the world. Accordingly, we believe that long-term investors in the Company will continue to be rewarded.
Chair
INVESTMENT OBJECTIVE AND POLICY
INVESTMENT OBJECTIVE
The Company invests in the global healthcare sector with the objective of achieving a high level of capital growth.
In order to achieve its investment objective, the Company invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It uses gearing, and derivative transactions to enhance returns and mitigate risk. Performance is measured against the MSCI World Health Care Index on a net total return, sterling adjusted basis (“Benchmark”).
INVESTMENT STRATEGY
The implementation of the Company’s Investment Objective has been delegated to OrbiMed by Frostrow (as AIFM) under the Board’s and Frostrow’s supervision and guidance.
Details of OrbiMed’s investment strategy and approach are set out in the Portfolio Manager’s Review.
While the Board’s strategy is to allow flexibility in managing the investments, in order to manage investment risk it has imposed various investment, gearing and derivative guidelines and limits, within which Frostrow and OrbiMed are required to manage the investments, as set out below.
Any material changes to the Investment Objective, Policy and Benchmark or the investment, gearing and derivative guidelines and limits require approval from shareholders.
INVESTMENT POLICY
INVESTMENT LIMITS AND GUIDELINES
· The Company will not invest more than 15% of the portfolio in any one individual stock at the time of acquisition;
·
At least 50% of the portfolio will normally be invested in larger companies (i.e. with a market capitalisation of at least U.S.
·
At least 20% of the portfolio will normally be invested in smaller companies (i.e. with a market capitalisation of less than U.S.
· Investment in unquoted securities will not exceed 10% of the portfolio at the time of acquisition;
· A maximum of 5% of the portfolio, at the time of acquisition, may be invested in each of debt instruments, convertibles and royalty bonds issued by pharmaceutical and biotechnology companies;
· A maximum of 30% of the portfolio, at the time of acquisition, may be invested in companies in each of the following sectors:
– healthcare equipment and supplies;
– healthcare providers and services;
·
The Company will not invest more than 10% of its gross assets in other closed ended investment companies (including investment trusts) listed on the
DERIVATIVE STRATEGY AND LIMITS
In line with the Investment Objective, derivatives are employed, when appropriate, in an effort to enhance returns and to improve the risk-return profile of the Company’s portfolio. Only Equity Swaps were employed within the portfolio during the year.
The Board has set the following limits within which derivative exposures are managed:
· Derivative transactions (excluding equity swaps) can be used to mitigate risk and/or enhance capital returns and will be restricted to a net exposure of 5% of the portfolio; and
· Equity Swaps may be used in order to meet the Company’s investment objective of achieving a high level of capital growth, and counterparty exposure through these is restricted to 12% of the gross assets of the Company at the time of acquisition.
The Company does not currently hedge against foreign currency exposure.
GEARING LIMIT
The Board has set a maximum gearing level, through borrowing, of 20% of the net assets.
LEVERAGE LIMITS
Under the AIFMD the Company is required to set maximum leverage limits. Leverage under the AIFMD is defined as any method by which the total exposure of an AIF is increased.
The Company has two current sources of leverage: the overdraft facility, which is subject to the gearing limit; and, derivatives, which are subject to the separate derivative limits. The Board and Frostrow have set a maximum leverage limit of 140% on both the commitment and gross basis.
Further details on the gearing and leverage calculations, and how total exposure through derivatives is calculated, are included in the Glossary. Further details on how derivatives are employed can be found in note 16.
PORTFOLIO
INVESTMENTS HELD AS AT
Investments Sector Country Market value % of £’000 Investments Eli Lilly Pharmaceuticals United States 192,261 9.2% Healthcare Boston Scientific Equipment & United States 139,752 6.7% SuppliesNovo Nordisk Pharmaceuticals Denmark 130,534 6.2% AstraZeneca Pharmaceuticals United Kingdom 129,973 6.2% Healthcare Intuitive Surgical Equipment & United States 123,124 5.9% Supplies Merck Pharmaceuticals United States 117,578 5.6% Biogen Biotechnology United States 92,990 4.4% Healthcare Tenet Healthcare Providers & United States 80,031 3.8% Services Daiichi Sankyo Pharmaceuticals Japan 77,991 3.7% Healthcare Stryker Equipment & United States 63,107 3.0% Supplies Top 10 investments 1,147,341 54.7% BioMarin Biotechnology United States 56,867 2.7% Pharmaceutical Healthcare Elevance Health Providers & United States 52,559 2.5% Services Eisai Pharmaceuticals Japan 52,016 2.5% Thermo Fisher Life Sciences Tools United States 51,937 2.5% Scientific & Services Healthcare Evolent Health Providers & United States 51,662 2.5% Services GSK Pharmaceuticals United Kingdom 50,940 2.4% Natera Life Sciences Tools United States 46,733 2.2% & Services Ionis Biotechnology United States 42,969 2.0% Pharmaceuticals Caris Life Sciences* Life Sciences Tools United States 40,531 1.9% & Services Sarepta Therapeutics Biotechnology United States 38,152 1.8% Top 20 investments 1,631,707 77.7% ICON Life Sciences Tools Ireland 37,515 1.8% & Services Apellis Biotechnology United States 37,187 1.8% Pharmaceuticals Argenx Biotechnology Netherlands 32,035 1.5% Neurocrine Biotechnology United States 29,086 1.4% Biosciences Healthcare SI-BONE Equipment & United States 29,033 1.4% Supplies Vertex Biotechnology United States 28,781 1.4% Pharmaceuticals Healthcare UnitedHealth Providers & United States 27,397 1.3% Services Vaxcyte Biotechnology United States 26,716 1.3% Cytokinetics Biotechnology United States 26,621 1.3%Shanghai INT Medical Healthcare Instruments Equipment & China 20,244 1.0% Supplies Top 30 investments 1,926,322 91.9% Janux Therapeutics Biotechnology United States 19,806 0.9% Healthcare Crossover Health* Providers & United States 18,018 0.9% Services EDDA Healthcare & Healthcare Technology* Equipment & China 15,129 0.7% Supplies VISEN Biotechnology China 13,714 0.7% Pharmaceuticals* Beijing Yuanxin Healthcare Technology* Providers & China 13,407 0.6% Services Sino Pharmaceuticals Hong Kong 12,723 0.6% Biopharmaceutical Healthcare Dexcom Equipment & United States 12,012 0.6% Supplies Galderma Group Pharmaceuticals Switzerland 11,652 0.6% New Horizon Health Life Sciences Tools China 11,186 0.5% & Services Innovent Biologics Biotechnology China 11,053 0.5% Top 40 investments 2,065,022 98.5% Healthcare Ruipeng Pet Group* Providers & China 10,844 0.5% Services Healthcare Jiangxi RiMAG Group* Providers & China 10,503 0.5% Services Healthcare MabPlex* Providers & China 5,395 0.3% Services Healthcare API Holdings* Providers & India 5,072 0.2% Services Shandong Weigao Healthcare Group Medical Equipment & China 2,961 0.1% Polymer Supplies Shanghai Bio-heart Healthcare Biological Equipment & China 2,381 0.1% Technology Supplies Passage Bio Biotechnology United States 2,218 0.1% Ikena Oncology Biotechnology United States 1,815 0.1% Dingdang Health Healthcare Technology Providers & China 1,510 0.1% Services Peloton Therapeutics Biotechnology United States 514 0.0% - Milestone* Total equities 2,108,235 100.5% Biotech M&A Target Basket Swaps United States 176,869 8.4% Swap Healthcare Apollo Hospitals Providers & India 16,416 0.8% Services GLP-1 Dislocation;/MedTech Basket Swaps China 4,797 0.2% Recovery Swap Less: Gross exposure (209,556) (10.0)% on financed swaps Total Equity Swaps (11,474) (0.5)% Total investments 2,096,761 100.0% including OTC Swaps
* Unquoted holding
SUMMARY
Investments Market value % of £’000 Investments Quoted Equities 1,975,108 94.2% Unquoted equities 133,127 6.3% Equity Swaps (11,474) (0.5)% Total of all investments 2,096,761 100.0%
PORTFOLIO MANAGER’S REVIEW
MARKETS
Global equity markets continued their rollercoaster ways in the financial year, with a volatile first half followed by a steep climb higher in the second half. One constant throughout the year has been the macroeconomic and political factors driving returns, trumping industry specific fundamentals.
The first half of the year was characterised mostly by investor fear and uncertainty, with rising interest rates, geopolitical conflicts, and persistent inflation providing the backdrop for the debate around a recession. Broad market returns during this period were flat to down, exacerbated by a precipitous market sell-off in October where “higher for longer” was the rally cry for investors to sell. Healthcare stocks eschewed their traditional defensive characteristics and lagged the market by over 5% (source: MSCI) during this period.
But the second half of the year saw a dramatic reversal of market performance as investors expressed enthusiasm over easing inflation data and the
The net of it was a difficult year for healthcare stocks. The MSCI World Index bucked the early tumult of the year to post an impressive total return of +22.4% (sterling). Whilst the MSCI World Healthcare Index also rebounded during the year, the total return of +10.9% (sterling) was the worst relative performance versus the broad market in over 20 years.
Despite the difficult backdrop for healthcare, the Company was able to produce a strong double-digit return that exceeded the Benchmark by over 1%, driven primarily by stock picking across Big Pharma, Emerging Biotech, and
ALLOCATION
We actively manage the Company’s allocation across healthcare sub-sectors with reference to the Benchmark. In the reported financial year, we have continued our strategic overweight positioning in Biotechnology stocks, in particular Emerging Biotech. As innovation has become the real hallmark of the Company, the real cradle of innovation has been in Emerging Biotech stocks, companies that are typically without revenues but have been the technology engine behind both the majority of the industry’s pipeline and ultimately new product approvals. We ended the financial year with total Biotechnology exposure of 29.0%, 20.7% above the Benchmark, representing an increase year-over-year on both an absolute and relative basis. Within Emerging Biotech, there was a modest increase year-over-year (+1.7%) on an absolute basis and a large increase relative to the Benchmark (+3.9%) as valuations compressed in the period. Overall, the exposure is very much consistent with our long-held positioning that has typically ranged from high 20’s to low 30’s percentage on an absolute basis, which we expect to continue.
Similarly, we have continued our strategic underweight positioning in Pharmaceutical stocks in the reported financial year. There are two main rationales for this. First is a nod to the Benchmark where Pharmaceuticals (global large capitalisation stocks, generics, and specialty) comprise approximately 45% of the weighting, the largest segment of MSCI World Healthcare Index. This fact creates the most likely candidate for funding other segments of our investment. Second, and more importantly, the underweight positioning is primarily due to our fundamental outlook for the sector. Big Pharma companies, in our view, are a collection of companies that are easily divided into the classic “Have or Have Not” designation from a variety of metrics including but certainly not limited to valuation, growth profile, management credibility, pipelines, new product launches, strength of balance sheet, capital allocation priorities, and forward-looking catalysts. Our focus on the “Haves” has enabled us to capture performance in the financial year both in absolute terms and relative to the Benchmark, despite the underweight positioning. Year-over-year, our exposure in Big Pharma companies did increase by 3.3% (absolute) and 1.3% (relative) given high conviction ideas in companies that are significant weightings in the Benchmark including
Eli Lilly
,
In the Life Sciences Tools & Services (“Tools”) sector, we increased our exposure over the course of the year but remained underweight versus the Benchmark, reflecting the difficult macro environment for tools companies across many markets, including bioprocessing, instruments,
ALLOCATION BY SUB-SECTOR
(WWH vs. MSCI World Healthcare Index)
As of 31 March 2024 As of 31 March 2023 Subsector ^WWH % NAV MSCI HC Over/Under ^WWH % NAV MSCI HC Over/Under vs.BM vs.BM Pharmaceuticals 31.0 44.8 (13.8) 26.8 43.0 (16.2) Big Pharma 29.9 41.7 (11.8) 26.6 39.7 (13.1) Spec Pharma 1.1 2.9 (1.8) 0.2 3.2 (3.0) Generics – 0.2 (0.2) – 0.1 (0.1) Biotechnology 29.0 8.3 20.7 24.1 9.4 14.7 Big Biotech 6.1 6.2 (0.1) 2.9 5.1 (2.2) Emerging Biotech 22.9 2.1 20.8 21.2 4.3 16.9 Life Science Tools & 6.5 11.1 (4.6) 3.8 12.3 (8.5) Services Health Care 17.8 16.9 0.9 19.3 16.2 3.1 Equipment & Supplies Healthcare Services 10.2 15.1 (4.9) 15.4 14.9 0.5 & Supplies Japan 6.3 3.8 2.5 6.3 4.2 2.1 Emerging Market 3.7 – 3.7 8.0 – 8.0 Privates 6.4 – 6.4 6.8 – 6.8 Total 110.9 100.0 10.9 110.5 100.0 10.5
^ Figures expressed as a % of total Net Asset Value. This includes all derivatives as an economically equivalent position in the underlying holding and allocated to the underlying holdings’ respective sectors and regions.
The portfolio allocation in Health Care Equipment & Supplies (“Medtech”) varied through the financial year given a variety of shifting tailwinds and headwinds. Whilst this is unlike our strategic positioning in Biotechnology and Pharmaceuticals, it is a typical trading pattern for us, historically, in
In Healthcare Providers & Services (“Services”), we reduced our managed care exposure meaningfully over the course of the year. Our current underweight positioning reflects the significant challenges that this sector has faced, especially for companies exposed to Medicare Advantage – including an unprecedented spike in utilisation and insufficient reimbursement updates from a more negative government stance on the industry. We are watching carefully for opportunities to increase our exposure again as utilisation appears to be stabilising.
Historically, our exposure to Japanese pharmaceuticals has been idea based. That is, our long history in both due diligence and investing in companies from
Another sector in which we have historically been overweight is Emerging Markets, in particular
PERFORMANCE
For the year ended
As detailed below, key upside drivers for performance included stock picking in Big Pharma, allocation and stock picking in Biotechnology, and stock picking in
SUBSECTOR PERFORMANCE
On a sub-sector level, the largest contributor to absolute performance was from Big Pharma, contributing 7% (of the +12% net asset value return). Obesity drugs and the landmark data from the newest GLP-1 medications was the true hallmark for healthcare stocks in 2023 and was a key contributor to the Company’s absolute performance. Stock picking here was key as relative contribution from Big Pharma was also positive, despite the sizable underweight positioning versus the Benchmark throughout the financial year (average portfolio weight 28% compared to Benchmark weight 41%).
An outsized contribution also came from
A contribution of import was also generated within Biotechnology, more specifically Emerging Biotech stocks which generated nearly 3% of absolute return. Moreover, this return also represented nearly 3% of relative return, primarily due to stock picking. The majority of this contribution came from OrbiMed’s custom and proprietary mergers and acquisitions (“M&A”) swap basket, first constructed in
Detractors of note on a sub-sector level (
Thus, allocation effect primarily led to more than a 2% negative impact from
In
UNQUOTEDS
During the financial year, the Company strategically refrained from making new investments in unquoted companies, as we continued to cautiously navigate the challenging public offering market for small and mid-capitalisation healthcare firms. While the capital market funding landscape has been improving, most of our unquoted companies are well capitalised and are being selective with regards to pursuing listings. We are optimistic about the ability of some of our unquoted investments to achieve listings within the next year as we anticipate the capital market funding environment will continue to improve.
As of the end of the financial year, unquoted investments made up 6.3% of the Company’s portfolio, a slight decrease from 6.7% as at
We participated in one additional investment (£3.3 million) in
During the year under review, the unquoted investments made a loss of £14.7 million, from an opening market value of £145.2 million across 10 companies. The unquoted strategy as a whole had an implied return of -9.9% which detracted
-
0.7% from performance.
ABSOLUTE CONTRIBUTION BY INVESTMENT FOR THE YEAR ENDED
Principal contributors to and detractors from net asset value performance
Contribution Top five Contribution contributors Sector Country per share £’000 p Eli Lilly Pharmaceuticals United States 77,301 13.2Novo Nordisk Pharmaceuticals Denmark 59,568 10.2 Intuitive Surgical Healthcare Equipment United States 49,032 8.4 & Supplies Boston Scientific Healthcare Equipment United States 36,022 6.2 & Supplies Tenet Healthcare Healthcare Providers United States 32,586 5.6 & Services
Contribution Contribution Top five detractors Sector Country per share £’000 p Bristol-Myers Squibb* Pharmaceuticals United States (12,246) (2.1) uniQure* Biotechnology Netherlands (15,647) (2.7) Eisai Pharmaceuticals Japan (16,628) (2.8) Madrigal Biotechnology United States (16,642) (2.8) Pharmaceuticals* Biogen Biotechnology United States (21,702) (3.7)
*
Not held at
MAJOR CONTRIBUTORS TO PERFORMANCE
The pursuit of innovation is the longtime hallmark of the Company. Nowhere has this been better exemplified than in the study and development of the incretin class of medicines, better known as the GLP-1 agonists or the now famous “obesity drugs” Wegovy (semaglutide) and Zepbound (tirzepatide). The journey of these medicines began in 1996 when the target was first isolated from the venom of a Gila monster and is now culminating in unprecedented benefit for patients with diabetes and obesity and a plethora of other indications, including cardiovascular disease, heart failure, chronic kidney disease, liver disease, just to name a few.
Eli Lilly
can call themselves one of the true pioneers in
this class of drugs and currently markets the undisputed “best-in-class” agents in the space. The company’s most recent offering is Mounjaro (tirzepatide), a dual GLP-1 and “GIP” agonist. Whilst approved for diabetes in 2022, the company presented additional data in obesity in 2023, showing weight loss eclipsing 20% and even approaching 25% in some cases. This dual-agonist therapy has pushed weight loss to new levels and the company benefited materially from the SELECT trial, with investors (and the company) assuming that “more is better”: the cardiovascular benefits shown by Wegovy should extend to Mounjaro, if not more so, given the superior weight loss profile. Sales of Mounjaro were annualising at almost
The other true pioneer of the GLP-1 class is the global sales leader in this space,
With a seasoned management team, multi-decade head start and superior robotic technology, we view
Intuitive Surgical
as the best positioned company in the
fast
-
growing and vastly under-penetrated surgical robotics space. The company operates as a monopoly with its
Boston Scientific
is an industry leading medical technology
company that develops, manufactures, and markets minimally invasive medical devices in several high growth end markets including interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation. Over the past year, the company has successfully driven accelerating organic sales growth ahead of company guidance and investor expectations on the back of several new product launches, improving labour issues at
The
MAJOR DETRACTORS FROM PERFORMANCE
In 2023, one of the most notable new drug approvals was Leqembi (lecanemab), the first monoclonal antibody to show unequivocal disease modifying effects in the treatment of mild to moderate Alzheimer’s disease. This landmark full approval was achieved by
Eisai
and their partner
Biogen
in
Furthermore, the dosing regimen for Leqembi requires a patient to receive a long duration intra-venous infusion once every two weeks at an appropriate infusion centre. Much of the infrastructure for this was limited or even absent in the first year of the launch, curbing access to “chair time” for patients to get this novel medication. As a result, uptake has been modest through the second half of 2023, although it has inflected in early 2024. This situation has weighed on the share prices of both Eisai and Biogen. Share price declines were exacerbated when delays arose to the companies’ sub - cutaneous formulation of Leqembi, a drug regimen that would circumvent the need for infusion centres and perhaps require less frequent administration and almost assuredly allow for greater uptake and utilisation of Leqembi in afflicted patients.
Ultimately, Eisai and Biogen failed to dose 10,000 patients in the
Madrigal Pharmaceuticals
is a clinical-stage
biopharmaceutical company based in
The global pharmaceutical company, Bristol-Myers Squibb is well known for its leadership in oncology, with major cancer franchises in both immuno-oncology and multiple myeloma. However, both franchises are aged and have reached or are nearing expiration of exclusivity. With a declining topline, the company’s price-to-earnings multiple has compressed to below 10x, creating the most heavily discounted stock in the large cap pharmaceutical space. However, this “value play” turned into a “value trap” in 2023. The company has had one of the most productive pipelines in the industry over the past three years, with new approvals in immunology, haematology, oncology, and cardiovascular disease. However, commercial execution of the many new product launches has underwhelmed, and a top line renaissance has so far failed to materialise. The share price has subsequently fallen further as has the multiple. We exited the stock during the first half of the financial year as our conviction level for a turnaround deteriorated. The share price continued to move lower in the second half of the year.
DERIVATIVE STRATEGY
The Company has the ability to utilise equity swaps and options as part of its financial strategy. Equity swaps are a financial tool, a derivative contract, that allow for synthetic exposure to a basket of single stocks in an efficient manner and within a well-defined theme. For example, having 15 to 50+ additional positions at smaller weights in the portfolio (i.e., non-core) is suboptimal. An equity swap basket facilitates management of the investment theme and tracking of performance. The swaps contain multiple single stock long positions and the basket swap counterparty is Goldman Sachs, allowing for confidence in forward trading and rebalancing strategies.
The Company strategically invested in three customised tactical basket swaps, targeting growth opportunities in undervalued small and mid-capitalisation biotech, therapeutic and medical device companies.
These baskets were constructed to capitalise on three prevailing themes: 1) investment opportunities possessing considerable potential as attractive acquisition targets for larger corporations (M&A swap basket), 2) those exhibiting a favourable risk/reward profile in light of upcoming clinical catalysts and 3) substantial valuation dislocations in small and mid-capitalisation medical device companies brought about by the GLP-1 weight loss craze.
During the period under review, the basket swaps gained £32.7 million, which added 1.6% to performance. The gains were primarily due to the returns generated by the propriety Biotech M&A Target Swap.
Throughout the year, the Company also used single stock equity swaps to access Chinese and Indian investments, which would otherwise be inaccessible through more traditional investment methods. During the period under review, single stock equity swaps contributed £5.0 million to performance, and we remain confident in the long-term prospects of emerging market securities, particularly those trading locally in mainland
LEVERAGE STRATEGY
Historically, the typical leverage level employed by the Company has been in the mid-to-high teens range. Considering the market volatility during the past three plus financial years, we have, more recently, used leverage in a more tactical fashion. In 2023, we have flexed leverage modestly in response to the economic climate, including in consideration of a putative recession earlier in the period and interest rate fluctuations and speculation.
Most recently, leverage has converged to the low-double digit range, a reflection of our overall bullishness on the portfolio and a hopeful turn in biotechnology stocks. Some factors that keep us from extending leverage even further is the continued uncertainty with the macro backdrop, further geopolitical risk, the looming
SECTOR DEVELOPMENTS
Innovation is one of the major value drivers across the healthcare space. One of the most objective measures of said innovation is novel product approvals and 2023 was record setting with 67 approvals across a wide range of therapeutic categories. More impressive has been the nearly 400 new drugs approved over the past 7 years. This
There were many notable new drugs among the more than five dozen approvals in 2023. As mentioned previously in this report was the landmark approval of Leqembi (lecanemab), the first monoclonal antibody to show unequivocal disease modifying effects in the treatment of mild to moderate Alzheimer’s disease, ushering in a new paradigm in helping patients and families with this devastating disease. GSK presided over the best (non - COVID) vaccine launch in history after the approval of Arexvy, indicated for seniors for active immunisation for the prevention of lower respiratory tract disease in patients exposed to Respiratory Syncytial Virus (RSV). Another medicine approved for RSV was Beyfortus (nirsevimab), a monoclonal antibody designed to prevent infections in newborns babies. Multiple novel gene therapies were also approved, including Elevidys for Duchenne Muscular Dystrophy (a genetic problem in producing dystrophin, a protein that protects muscle fibers from breaking down, a disease found in young boys which results in the inability to crawl or walk and early death) and Roctavian for Haemophilia A (a genetic disorder resulting from a deficit of factor VIII, a vital blood - clotting protein, that manifests as protracted and excessive bleeding either spontaneously or secondary to trauma).
A significant investment theme in 2023 – a theme we expect to continue into 2024 – is the accelerated pace of mergers and acquisitions in the therapeutics space, fuelled by a variety of factors. First, the industry is facing another “patent cliff” with approximately U.S.
This has created a very positive environment for deal making as high interest rates and a quiet initial public offering market created some barriers to access for capital for these companies. The financial year saw a total of 40
-
bio
-
pharmaceutical takeovers valued at U.S.
INNOVATION
The largest sector development continues to be the incredible era of innovation that the bio-pharmaceutical industry is presiding over. The global phenomenon of obesity drugs that gripped the market in 2023 actually represents a class of drugs that is nearly 20 years old, but the continued innovation by the pioneers – Eli Lilly and
Capital expenditure exceeding U.S.
Another key tailwind for this class of drugs is also usage outside of “diabesity” with impressive clinical data for cardiovascular disease, heart failure, osteoarthritis, kidney disease, liver, and sleep apnea already published. Over the coming year we should see data in other indications as well, such as peripheral arterial disease and even Alzheimer’s disease. An independent study out of
As 2023 came to a close, the latest generation GLP-1’s were annualising at U.S.
A therapeutic class that has been a hot bed of innovation over the past decade has been oncology. The launch of the first “immuno-oncology” agent ushered in a revolution in the treatment of cancer never before seen and despite the bar constantly resetting higher, the industry continues to deliver as “IO” agents eclipsed U.S.
Not to be outdone, but the largest inflection of interest in the oncology space over the past year has been in the antibody-drug-conjugate (ADC) class of drugs. ADCs are a form of targeted medicines that deliver chemotherapy agents directly to cancer cells, destroying them whilst mostly sparing normal, healthy cells. The pursuit of ADCs was behind the largest business development deals in 2023, specifically the U.S.
Radiopharmaceuticals – the using of localised radiation in the form of injectable isotopes – was another area of oncology which saw outsized M&A activity with Eli Lilly, AstraZeneca, and
With record new drug approvals and clinical pipelines as full as they have ever been, this impressive wave of innovation will be bountiful in 2024 and for years to come. Whilst our focus here has been on metabolic disease and oncology, by no means are new achievements in innovation limited to these therapeutic classes. 2023 saw the approval of the very first disease modifying agent for Alzheimer’s disease (Eisai’s Leqembi). 2023 saw the approval of the very first vaccine for respiratory syncytial virus (GSK’s Arexvy). 2023 saw the first approval for a gene therapy treatment for Duchenne muscular dystrophy (Sarepta Therapeutic’s Elevidys). Early 2024 saw the approval of the most sophisticated surgical robotic suite ever produced (Intuitive Surgical’s
Now in our 29th year, the performance from inception remains strong. As we closed the financial year, the NAV was near all-time highs and our bullishness into the new financial year remained steadfast. Overall, the Company’s net asset value performance since inception (from
OUTLOOK
The state of the healthcare industry remains strong, supported by significant global demand and new product flow, underpinned by an era of incredible innovation that has not been seen before. Moreover, the challenging investment backdrop for healthcare stocks that has been in place since the easing of the COVID pandemic appears to be in the past as the recent inflection of share prices across the industry is much more indicative of the positive fundamentals of the space. The long-term growth potential of healthcare also remains strong: global demographics, aging populations, and constant, persistent demand. Innovation, however, continues to advance in unparalleled fashion and is the primary driver of value creation. Innovation is not just in the domain of biotechnology, but across therapeutics, medical technology, patient services, analytics, and platform technologies. Together, they are improving patient care, advancing medical knowledge, and creating new medicines, with many that now can offer a cure. The productivity in the therapeutics space continues to be exceptional, with pipelines the fullest they have ever been, and the number of new drug approvals at all - time highs. The inflection in M&A in the space is just one testimony to this productivity, one that has already continued in 2024.
Overall, we remain committed to our long-term investment strategy that has underpinned our impressive track record since inception. There is no change to our investment philosophy and we eschew change for its own sake. We look forward to what the year ahead brings, across the entirety of the healthcare spectrum, as the growth of this industry continues to create a multitude of exciting investment opportunities.
Portfolio Manager
ENVIRONMENTAL, SOCIAL AND GOVERNANCE AND CLIMATE CHANGE
ORBIMED’S APPROACH TO ESG
The Company’s Portfolio Manager, OrbiMed, is guided by its Responsible Investing Policy in its approach to environmental, social, and governance (“ESG”). They seek to invest in innovative healthcare companies that are working towards addressing significant unmet medical needs, across biopharmaceuticals, medical devices, diagnostics, and healthcare services sectors, globally.
OrbiMed believes that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value. The Portfolio Manager seeks to integrate ESG into the overall investment process, with the objective of maximising investment returns. Investment decisions are based on a variety of financial and non-financial company factors, including ESG information. The Portfolio Manager has appointed a full-time member of staff to the role of Director – ESG to oversee the integration of ESG analysis.
As a responsible investor, OrbiMed negatively screens potential investments and business sectors that may objectively lead to negative impacts on public health or well-being. They consider healthcare sector-specific guidance from the
MONITORING AND ENGAGEMENT
OrbiMed utilises ESG scores for public equity holdings from third-party service providers. To supplement the information from the third-party service providers, OrbiMed also conducts proprietary analysis on ESG performance. The scores from the third-party service providers are integrated with OrbiMed’s analysis onto a business intelligence platform via programming interface, for regular monitoring.
The Portfolio Manager also engages on a regular basis with its portfolio companies through meetings with management, proxy voting, and in some cases, through board representation.
OrbiMed’s analysts regularly track ESG information on safety of clinical trials, drug safety, product safety, ethical marketing, call-backs and other materially relevant factors. As part of these efforts, OrbiMed engages with companies directly or through brokers, and facilitates dialogues and exchange of leading practices among investors, companies, and other relevant experts on ESG in the healthcare sector.
Between
Number of votes against Proposed by Total number Voted for Voted against Votes abstained of proposals management’s proposed response Management 607 562 45 0 45 5Shareholder 19 2 17 0 2
There were no management proposals referring to ESG that came to vote. Of the 19 shareholder proposals, there was one proposal regarding diversity, equity and inclusion report and another proposal regarding impact of extension of patents on access. ‘Access to medicine’ is one of the material ESG topics listed in the
The Portfolio Manager provides a quarterly update on ESG to the Board of the Company.
CLIMATE CHANGE
As per the guidance from SASB, climate change in relation to the Company’s own operations is not a material ESG consideration for biotechnology and pharmaceutical, medical equipment and supplies, and managed care sectors. However, Energy management is noted as a material ESG concern for the healthcare delivery sector. To that end, OrbiMed includes the scores on energy management for the relevant sectors in its overall ESG monitoring.
REGULATORY UPDATE ON ESG
During the year, regulators around the world remained active on defining and classifying ESG investing and curbing greenwashing.
While the Portfolio Manager considers ESG issues to be important when selecting investments, the Company does not have explicit sustainability objectives in its investment policy and the Company will not seek to apply a sustainability label under SDR.
Portfolio Manager
BUSINESS REVIEW
The Strategic Report contains a review of the Company’s business model and strategy, an analysis of its performance during the financial year and its future developments and details of the principal risks and challenges it faces. Its purpose is to inform shareholders in the Company and help them to assess how the Directors have performed their duty to promote the success of the Company.
The Strategic Report contains certain forward-looking statements. These statements are made by the Directors in good faith based on the information available to them up to the date of this report. Such statements should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying such forward-looking information.
BUSINESS MODEL
The purpose of the Company is to achieve a high level of capital growth for its shareholders by providing a vehicle for investors to gain, through a single investment, exposure to the global healthcare sector through a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities.
The Company’s strategy is to create value for shareholders by addressing its investment objective.
As an externally managed investment trust, all of the Company’s day-to-day managements and administrative functions are outsourced to service providers. As a result, the Company has no executive directors, employees or internal operations. The Company employs
The Company is an investment company within the meaning of Section 833 of the Companies Act 2006 and has been approved by HM Revenue & Customs as an investment trust (for the purposes of Section 1158 of the Corporation Tax Act 2010). As a result the Company is not liable for taxation on capital gains. The Directors have no reason to believe that approval will not continue to be retained. The Company is not a close company for taxation purposes.
The Board is responsible for all aspects of the Company’s affairs, including the setting of parameters for and the monitoring of the investment strategy a s well as the review of investment performance and policy. It also has responsibility for all strategic issues, the dividend policy, the share issuance and buy-back policy, gearing, share price and discount/premium monitoring and corporate governance matters.
CONTINUATION OF THE COMPANY
A resolution was passed at the Annual General Meeting (“AGM”) held in 2019 that the Company continues as an investment trust for a further five year period. In accordance with the Company’s Articles of Association, shareholders will have an opportunity to vote on the continuation of the Company at this year’s AGM and every five years thereafter.
THE BOARD
All Directors, with the exception of
DIVIDEND POLICY
It is the Company’s policy to pay out dividends to shareholders at least to the extent required to maintain investment trust status for each financial year. Such dividends will typically be paid twice a year by means of an interim dividend and a final dividend.
KEY PERFORMANCE INDICATORS (“KPIs”)
The Board assesses the Company’s performance in meeting its objectives against KPI’s as follows. The KPI’s have not changed from the previous year:
· Net asset value (“NAV”) per share total return against the Benchmark;*
· Discount/premium of share price to NAV per share; and
· Ongoing charges ratio.*
* Alternative Performance Measure (See Glossary)
Information on the Company’s performance is provided in the Statement from the Chair and the Portfolio Manager’s Review and a record of these measures is shown in the Strategic Report. Further information can be found in the Glossary.
NAV per share total return against the Benchmark
The Directors regard the Company’s NAV per share total return as being the overall measure of value delivered to shareholders over the long term. This reflects both net asset value growth of the Company and dividends paid to shareholders.
The Board considers the most important comparator, against which to assess the NAV per share total return performance, to be the MSCI World Health Care Index measured on a net total return, sterling adjusted basis (the ‘Benchmark’). As noted in the Strategic Report, OrbiMed has flexibility in managing the investments and are not limited by the makeup of the Benchmark. As a result, investment decisions are made that differentiate the Company from the Benchmark and therefore the Company’s performance may also be different from that of the Benchmark.
A full description of performance during the year under review is contained in the Portfolio Manager’s Review.
Share price discount/premium to NAV per share
The share price discount/premium to the NAV per share is considered a key indicator of performance as it impacts the share price total return of shareholders and can provide an indication of how investors view the Company’s performance and its Investment Objective.
Ongoing charges*
The Board continues to be conscious of expenses and works hard to maintain a balance between good quality service and costs.
As at
* Alternative Performance Measure (See Glossary).
PRINCIPAL SERVICE PROVIDERS
The principal service providers to the Company are the AIFM, Frostrow, the Portfolio Manager, OrbiMed, the
Alternative investment fund manager (“AIFM”)
Frostrow under the terms of its AIFM agreement with the Company provides, inter alia , the following services:
·
oversight of the portfolio management function delegated to
· portfolio administration and valuation;
· risk management services;
· marketing and shareholder services;
· share price discount and premium management;
· administrative and secretarial services;
· advice and guidance in respect of corporate governance requirements;
· maintenance of the Company’s accounting records;
· maintenance of the Company’s website;
· preparation and dispatch of annual and half-year reports (as applicable) and monthly fact sheets; and
· ensuring compliance with applicable legal and regulatory requirements.
During the year, under the terms of the AIFM Agreement, Frostrow received a fee as follows:
On market capitalisation up to £150 million: 0.3%; in the range £150 million to £500 million: 0.2%; in the range £500 million to £1 billion: 0.15%; in the range £1 billion to £1.5 billion: 0.125%; over £1.5 billion: 0.075%. In addition, Frostrow receives a fixed fee per annum of £57,500.
Portfolio manager
OrbiMed under the terms of its portfolio management agreement with the AIFM and the Company provides, inter alia, the following services:
· the seeking out and evaluating of investment opportunities;
· recommending the manner by which monies should be invested, disinvested, retained or realised;
· advising on how rights conferred by the investments should be exercised;
· analysing the performance of investments made; and
· advising the Company in relation to trends, market movements and other matters which may affect the investment objective and policy of the Company.
OrbiMed receives a base fee of 0.65% of NAV and a performance fee of 15% of outperformance against the Benchmark as detailed in the Report of the Directors.
Depositary, custodian and prime broker
The Depositary receives a variable fee based on the size of the Company as set out in the Report of the Directors.
· safekeeping and custody of the Company’s investments and cash;
· processing of transactions;
· provision of an overdraft facility. Assets up to 140% of the value of the outstanding overdraft can be taken as collateral; and
· foreign exchange services.
AIFM AND PORTFOLIO MANAGER EVALUATION AND RE-APPOINTMENT
The performance of the AIFM and the Portfolio Manager is reviewed continuously by the Board and the
The Board believes the continuing appointment of the AIFM and the Portfolio Manager is in the interests of shareholders as a whole. In coming to this decision, it took into consideration, inter alia , the following:
· the quality of the service provided and the depth of experience of the company management, company secretarial, administrative and marketing team that the AIFM allocates to the management of the Company; and
· the quality of the service provided and the quality and depth of experience allocated by the Portfolio Manager to the management of the portfolio and the long-term performance of the portfolio in absolute terms and by reference to the Benchmark.
RISK MANAGEMENT
The Board is responsible for the management of risks faced by the Company. Through delegation to the
Principal risks and uncertainties Mitigation Market risks By the nature of its activities and Investment Objective, the Company’s To manage these risks the Board and the portfolio is exposed to fluctuations in AIFM have appointed OrbiMed to manage market prices (from both individual the portfolio within the remit of the security prices and foreign exchange investment objective and policy, and rates) and due to exposure to the imposed various limits and guidelines. global healthcare sector, it is These limits ensure that the portfolio expected to have higher volatility than is diversified, reducing the risks the wider market. As such investors associated with individual stocks, and should be aware that by investing in that the maximum exposure (through the Company they are exposing derivatives and an overdraft facility) themselves to market risks and those is limited. The compliance with those additional risks specific to the limits and guidelines is monitored daily sectors in which the Company invests, by Frostrow and OrbiMed and reported to such as political interference in drug the Board monthly. pricing. In addition, OrbiMed reports at each In addition, OrbiMed’s approach is Board meeting on the performance of the expected to lead to performance that Company’s portfolio, which encompasses will deviate from that of comparators, the rationale for stock selection including both market indices and other decisions, the make-up of the portfolio, investment companies investing in potential new holdings and, derivative healthcare. activity and strategy (further details on derivatives can be found in note 16). The Company also uses leverage (both through derivatives and gearing) the The Company does not currently hedge its effect of which is to amplify the gains currency exposure. or losses the Company experiences. Geopolitical/regulatory and macro economic risk While such events are outside the control of the Company the Board reviews regularly, and discusses with the Portfolio Manager, the wider economic and political environment, along with the portfolio exposure and the execution of the investment policy against the long-term objectives of the Company. The Macro events may have an adverse impact ongoing tensions in theAsia Pacific on the Company’s performance by causing Region and also the instability caused exchange rate volatility, changes in by the war in theUkraine have featured tax or regulatory environments, and/or in these discussions. The Portfolio a fall in market prices. Emerging Manager’s risk team perform systematic markets, which a portion of the risk analysis, including country and portfolio is exposed to, can be subject industry specific risk monitoring. to greater political uncertainty and price volatility than developed The Board monitors regulatory markets. developments but relies on the services of its external advisers to ensure compliance with applicable law and regulations. The Board has appointed a specialist investment trustAIFM and Company Secretarywho provides industry and regulatory updates at each Board meeting. Unquoted investment risk The Company’s risk could be increased by its investment in unquoted To mitigate this risk the Board and AIFM companies. These investments may be have set a limit of 10% of the more difficult to buy, sell or value, portfolio, calculated at the time of so changes in their valuations may be investment, that can be held in unquoted greater than for listed assets. The investments and have established a valuation of unquoted investments robust and consistent valuation policy requires considerable judgement as and process as set out in Note 1(b), explained in Note1(a) and as such which is in line withUK GAAP realisations may be materially lower requirements and the International than the value as estimated by thePrivate Equity and Venture Capital Company. Particular events, outside the (“IPEV”) Guidelines. The Board also control of the Company, may also have a monitors the performance of these significant impact on the valuation and investments compared to the additional considerable uncertainty may exist risks involved. around the potential future outcomes for each investment. Investment management key person risk The Board manage this risk by: · appointing OrbiMed,who operate a team environment such that the loss of any individual should not impact on service levels; · receiving reports from OrbiMed at each Board meeting, such report includes any significant changes in the make-up of There is a risk that the individuals the team supporting the Company; responsible for managing the Company’s portfolio may leave their employment or · meeting the wider team, outside the may be prevented from undertaking their designated lead managers, at OrbiMed’s duties. offices and encouraging the participation of the wider OrbiMed team in investor updates; and · delegating to the ManagementEngagement & Remuneration Committee responsibility to perform an annual review of the service received from OrbiMed, including, inter alia, the team supporting the lead managers and succession planning. Counterparty risk This risk is managed by the Board through: In addition to market and foreign currency risks, discussed above, the · reviews of the arrangements with, and Company is exposed to risk arising from services provided by, the Depositary and the use of counterparties. If a the Custodian and Prime Broker to ensure counterparty were to fail, the Company that the security of the Company’s could be adversely affected through assets is being maintained. Legal either delay in settlement or loss of opinions are sought, where appropriate, assets. as part of this review. Also, the Board regularly monitors the credit rating of The most significant counterparty the the Company’s Custodian and Prime Company is exposed to is J.P. Morgan Broker;Securities LLC which is responsible for the safekeeping of the Company’s assets · monitoring of the assets taken as and provides the overdraft facility to collateral (further details can be found the Company. As part of the in note 16); arrangements withJ.P. Morgan Securities LLC they may take assets, up · reviews of OrbiMed’s approved list of to 140% of the value of the drawn counterparties, the Company’s use of overdraft, as collateral and have first those counterparties and OrbiMed’s priority security interest or lien over process for monitoring, and adding to, all of the Company’s assets. Such the approved counterparty list; assets taken as collateral may be used, loaned, sold, rehypothecated or · monitoring of counterparties, transferred byJ.P. Morgan Securities including reviews of internal control LLC. Although the Company maintains the reports and credit ratings, as economic benefit from the ownership of appropriate; those assets it does not hold any of the rights associated with those · by primarily investing in markets that assets. Any of the Company’s assets operate DVP (Delivery Versus Payment) taken as collateral are not covered by settlement. The process of DVP mitigates the custody arrangements provided by the risk of losing the principal of aJ.P. Morgan Securities LLC . The Company trade during the settlement process; and is, however, afforded protection in accordance withSEC rules andU.S. ·J.P. Morgan Securities LLC is subject legislation equal to the value of the to regular monitoring by J.P. Morgan assets that have been rehypothecated.Europe Limited , the Company’s Depositary, and the Board receives regular reports fromJ.P. Morgan Europe Limited . Service provider risk To manage these risks the Board: · receives a monthly compliance report from Frostrow, which includes, inter alia, details of compliance with applicable laws and regulations; · reviews internal control reports, key policies, including measures taken to combat cyber security issues, and also The Company is reliant on the systems the disaster recovery procedures of its of its service providers and as such service providers; disruption to, or a failure of, those systems (including, for example, as a · maintains a risk matrix with details result of cyber-crime or a ‘black swan’ of risks the Company is exposed to, the event) could lead to a failure to controls relied on to manage those risks comply with law and regulations leading and the frequency of the controls to reputational damage and/ or operation; financial loss. · receives updates on pending changes to the regulatory and legal environment and progress towards the Company’s compliance with these; and · has considered the increased risk of cyber-attacks and received reports and assurance at meetings with its service providers where the information security controls in place were reviewed. ESG related risks The Portfolio Manager provides ESG reports at each Board meeting, Both the Board and the Portfolio highlighting examples where ESG issues Manager recognise the importance of influenced investment decisions and/or having a coherent ESG policy. There is led to engagement with an investee a risk that investing in companies that company. The Portfolio Manager also disregard ESG factors will have a produces a quarterly ESG update. negative impact on investment returns and also that the Company itself may The Board ensures that the Portfolio become unattractive to investors if ESG Manager’s ESG approach is in line with is not appropriately considered in the standards elsewhere and the Board’s Portfolio Manager’s decision making expectations. A summary of the Portfolio process. Manager’s approach to Responsible Investing can be found in the Strategic Report. Shareholder relations and share price performance risk In managing this risk the Board: · reviews the Company’s Investment Objective in relation to market, and economic, conditions and the operation of the Company’s peers; · discusses at each Board meeting the The Company is also exposed to the Company’s future development and risk, particularly if the investment strategy; strategy and approach are unsuccessful, that the Company may underperform · reviews the shareholder register at resulting in the Company becoming each Board meeting; unattractive to investors and a widening of the share price discount to · actively seeks to promote the Company NAV per share. Also, falls in stock to current and potential investors; and markets and the risk of a global recession, are likely to adversely · has implemented a discount/premium affect the performance of the Company’s control mechanism. shares. The Board undertakes a regular review of the Company’s share price compared to the NAV per share. Further information can be found in the Business Review. Company promotional activities have been delegated to Frostrow,who report to the Board at each Board meeting on these activities.
Emerging risks
The Company has carried out a robust assessment of the Company’s emerging and principal risks and the procedures in place to identify emerging risks are described below.
During the year the
COMPANY PROMOTION
The Company has appointed Frostrow to provide marketing and investor relations services, in the belief that a well - marketed investment company is more likely to grow over time, have a more diverse and stable shareholder register and will trade at a superior rating to its peers.
Frostrow actively promotes the Company in the following ways:
Engaging regularly with institutional investors, discretionary wealth managers and a range of execution-only platforms:
Frostrow regularly talks and meets with institutional investors, discretionary wealth managers and execution-only platform providers to discuss the Company’s strategy and to understand any issues and concerns, covering both investment and corporate governance matters;
Making Company information more accessible: Frostrow works to raise the profile of the Company by targeting key groups within the investment community, holding annual investment seminars, overseeing PR output and managing the Company’s website and wider digital offering, including Portfolio Manager videos and social media;
Disseminating key Company information: Frostrow performs the Investor Relations function on behalf of the Company and manages the investor database. Frostrow produces all key corporate documents, distributes monthly Fact Sheets, Annual Reports and updates from OrbiMed on portfolio and market developments; and
Monitoring market activity, acting as a link between the Company, shareholders and other stakeholders: Frostrow maintains regular contact with sector broker analysts and other research and data providers, and conducts periodic investor perception surveys, liaising with the Board to provide up-to-date and accurate information on the latest shareholder and market developments.
DISCOUNT/PREMIUM CONTROL
The Board undertakes a regular review of the level of discount/premium and consideration is given to ways in which share price performance may be enhanced, including the effectiveness of marketing, share issuance and share buybacks, where appropriate.
It is the Board’s policy to buy back the Company’s shares if the share price discount to the net asset value per share exceeds 6% on an ongoing basis. Shares repurchased are held as treasury shares.
While buybacks may prove unable to prevent the discount from widening, they also enhance the net asset value per share for remaining shareholders and go some way to dampening discount volatility which can adversely affect investors’ risk adjusted returns.
At times when there are unsatisfied buying orders for the Company’s shares in the market, the Company has the ability to issue new shares or to re-issue treasury shares at a small premium to the cum income net asset value per share. This acts as an effective share price premium management tool.
Details of share issuance and share buybacks are set out in the Report of the Directors.
SOCIAL, HUMAN RIGHTS AND ENVIRONMENTAL MATTERS
The Directors, through the Company’s Portfolio Manager, encourage companies in which investments are made to adhere to best practice with regard to corporate governance. In light of the nature of the Company’s business there are no relevant human rights issues and the Company does not have a human rights policy.
The Company recognises that social and environmental issues can have an effect on some of its investee companies.
The Company is an investment trust and so its own direct environmental impact is minimal. As an externally- managed investment trust, the Company does not have any employees or maintain any premises, nor does it undertake any manufacturing or other physical operations itself. All its operational functions are outsourced to third party service providers. Therefore, the Company has no material, direct impact on the environment or any particular community and the Company itself has no environmental, human rights, social or community policies. The Board of Directors consists of six Directors, four of whom are resident in the
The Portfolio Manager engages with the Company’s underlying investee companies in relation to their corporate governance practices and the development of their policies on social, community and environmental matters.
INTEGRITY AND BUSINESS ETHICS
The Company is committed to carrying out business in an honest and fair manner with a zero-tolerance approach to bribery, tax evasion and corruption. As such, policies and procedures are in place to prevent this. In carrying out its activities, the Company aims to conduct itself responsibly, ethically and fairly, including in relation to social and human rights issues.
The Company believes that high standards of ESG make good business sense and have the potential to protect and enhance investment returns. The Portfolio Manager’s investment criteria provide that ESG and ethical issues are taken into account and best practice is encouraged by the Board. The Board’s expectations are that its principal service providers have appropriate governance policies in place.
TASKFORCE FOR CLIMATE-RELATED FINANCIAL DISCLOSURES (“TCFD”)
The Company notes the TCFD recommendations on climate-related financial disclosures. The Company is an investment trust with no employees, internal operations or property and, as such, it is exempt from the Listing Rules requirement to report against the TCFD framework.
GOING CONCERN
The financial statements have been prepared on a going concern basis. The Directors consider this is the appropriate basis as the Company has adequate resources to continue in operational existence for the foreseeable future, being taken as 12 months after approval of the financial statements. The Company’s shareholders are asked every five years to vote for the continuation of the Company, this will next be put to shareholders at this year’s Annual General Meeting. The content of the Company’s portfolio, trading activity, the Company’s cash balances and revenue forecasts, and the trends and factors likely to affect the Company’s performance are reviewed and discussed at each Board meeting. The Board has considered a detailed assessment of the Company’s ability to meet its liabilities as they fall due, including stress and liquidity tests which modelled the effects of substantial falls in markets and significant reductions in market liquidity, on the Company’s net asset value, its cash flows and its expenses. Further information is provided in the Audit & Risk Committee Report.
Based on the information available to the Directors at the date of this report, including the results of these stress tests, the conclusions drawn in the Viability Statement, the Company’s cash balances, and the liquidity of the Company’s listed investments, the Directors are satisfied that the Company has adequate financial resources to continue in operation for at least the next 12 months and that, accordingly, it is appropriate to continue to adopt the going concern basis in preparing the financial statements.
VIABILITY STATEMENT
The Directors have assessed the Company’s position and prospects, including consideration of the Company’s principal risks, and have formed a reasonable expectation that the Company will be able to continue in operation and meet its liabilities as they fall due over the next five financial years. The Board has chosen a five-year horizon in view of both the long-term outlook adopted by the Portfolio Manager when making investment decisions and also the investment horizon adopted by investors.
To make this assessment, the
· The portfolio is comprised principally of investments traded on major international stock exchanges. Based on recent market volumes 96.0% of the current portfolio could be liquidated within 5 trading days. There is no current expectation that the nature of the investments held within the portfolio will be significantly different in future.
· The Board has considered the viability of the Company under various scenarios, including periods of stock market and economic volatility, and concluded that it would expect to be able to ensure the financial stability of the Company due, in large part, to having a diversified portfolio comprising principally of listed and readily realisable assets. As illustrated in note 16 to the financial statements, the Board has considered the following risks with appropriate sensitivity analysis having been undertaken: market risk (including foreign currency risk, interest rate risk and other price risk), liquidity risk and credit risk.
With an ongoing charges ratio of 0.9%, the expenses of the Company are predictable and modest in comparison with the assets and there are no known capital commitments which would alter that position.
·
The Company has an overdraft facility which can be used to meet its liabilities. Details of the Company’s current liabilities as at
· The Company has no employees. Therefore, it does not have redundancy or other employment related liabilities or responsibilities.
· There will continue to be demand for investment trusts;
· The Portfolio Manager will continue to adopt a long-term view when making investments;
· The Company invests principally in the securities of listed companies traded on international stock exchanges to which investors will wish to continue to have exposure;
· Shareholders will vote for the continuation of the Company at this year’s Annual General Meeting and at five-year intervals thereafter. Following a programme of extensive engagement with the Company’s principal shareholders, there is an expectation that the resolution will be passed.
· Due to the closed-ended nature of the Company, unlike open-ended funds, it does not have to sell investments when shareholders wish to sell their shares;
· The Company will continue to be able to fund share buybacks when required. The Company bought back 80,265,298 shares in the year under review at a total cost of £252.7 million. It had shareholders’ funds in excess of £2,081.2 million at the year-end; and
· The long-term performance of the Company will continue to be satisfactory.
STAKEHOLDER INTERESTS AND BOARD DECISION-MAKING (SECTION 172 OF THE COMPANIES ACT 2006)
The Directors are required to explain more fully how they have discharged their duty under s172 of the Companies Act 2006 in promoting the success of the Company for the benefit of the members as a whole. This includes the likely consequences of the Directors’ decisions in the long term and how they have taken wider stakeholders’ needs into account.
The Directors aim to act fairly between the Company’s stakeholders. The Board’s approach to shareholder relations is summarised in the Corporate Governance Report. The Statement from the Chair provides an explanation of actions taken by the Directors during the year to achieve the Board’s long-term aim of ensuring that the Company’s shares trade at a price close to the NAV per share.
As an externally managed investment trust, the Company has no employees, customers, operations or premises. Therefore, the Company’s key stakeholders (other than its shareholders) are considered to be its service providers. The need to foster business relationships with the service providers and maintain a reputation for high standards of business conduct are central to the Directors’ decision-making as the Board of an externally managed investment trust. The Directors believe that fostering constructive and collaborative relationships with the Company’s service providers will assist in their promotion of the success of the Company for the benefit of all shareholders.
The Board engages with representatives from its service providers throughout the year. Representatives from OrbiMed and Frostrow are in attendance at each Board meeting. As the Portfolio Manager and the AIFM respectively, the services they provide are fundamental to the long-term success and smooth running of the Company. The Statement from the Chair and the Business Review, describe relevant decisions taken during the year relating to OrbiMed and Frostrow. Further details about the matters discussed in Board meetings and the relationship between OrbiMed and the Board are set out in the Corporate Governance Report.
Representatives from other service providers are asked to attend Board meetings when deemed appropriate.
Further details are set out overleaf.
The benefits of engagement How the board, the portfolio Stakeholder group with the Company's manager and the AIFM have stakeholders engaged with the Company’s stakeholders The Portfolio Manager and Frostrow, on behalf of the Board, complete a programme of investor relations throughout the year. In advance of this year’s continuation vote, the Chair of the Board, the Portfolio Manager and Frostrow undertook a series of meetings with the Company’s principal shareholders. The purpose of these meetings was two fold: to give holders the opportunity to raise issues of a corporate governance nature and to discuss any portfolio related matters. An analysis of the Company’s shareholder register is provided to the Directors at each Board meeting along with marketing reports from Frostrow. The Board reviews and considers the marketing plans Clear communication of the on a regular basis. Reports Company’s strategy and the from the Company’s broker are performance against the submitted to the Board on Company’s objective can help investor sentiment and industry the share price trade at a issues. narrower discount or a premium to its net asset value per Key mechanisms of engagement share which benefits include: shareholders. · The Annual General Meeting, Investors New shares can be issued to where the Portfolio Manager meet demand without net asset provides an update on the value per share dilution to Company’s performance and existing shareholders. strategy. This is followed by a Increasing the size of the question and answer section. Company can benefit liquidity as well as spread costs. · The Company’s website which hosts reports, articles and Share buybacks are undertaken insights, and monthly fact at the discretion of the sheets. Directors. · One-on-one and group investor meetings. · Should any significant votes be cast against a resolution proposed at the Annual General Meeting the Board will engage with shareholders. · The Board will explain in its announcement of the results of the Annual General Meeting any actions it intends to take to consult shareholders in order to understand the reasons behind significant votes against. · Following any consultation, an update would be published no later than six months after the Annual General Meeting and the Annual Report will detail the impact shareholder feedback has had on any decisions the Board has taken and any actions or resolutions proposed.
What were the key areas of engagement? What actions were taken, including main decisions? · The Portfolio Manager and Frostrow meet regularly with shareholders and potential investors to discuss the Company’s strategy, performance and portfolio. The Chair of the Board also met with key shareholders during the year to discuss corporate governance matters and also the Company’s investment strategy. Frostrow and the Portfolio Manager engage with retail investors through a number of different channels: Key areas of engagement with investors (i) The Company’s website, which is maintained by Frostrow, contains · Ongoing dialogue with shareholders articles, webinars and quarterly concerning the strategy of the Company, updates; performance and the portfolio. (ii) A distribution list of shareholders (retail and professional) which is maintained by Frostrow and is used to communicate with investors on a regular basis; (iii) The Portfolio Manager provides annual presentations online – (webcasts) and offline (Annual General Meeting), which shareholders are able to attend and participate in; and (iv) Frostrow ensures that the Company is available through a wide range of leading execution only platforms.
The benefits of engagement How the board, the portfolio Stakeholder group with the Company's manager and the AIFM have stakeholders engaged with the Company’s stakeholders Engagement with the Company’s The Board met regularly with Portfolio Manager is necessary the Company’s Portfolio Manager to evaluate their performance throughout the year. The Board against the Company’s stated also receives monthly strategy and to understand any performance and compliance risks or opportunities this reporting. may present. The Board ensures that the Portfolio Manager’s The Portfolio Manager’s environmental, social and attendance at each Board governance (“ESG”) approach is meeting provides the in line with standards opportunity for the Portfolio elsewhere and the Board’s Manager and Board to further expectations. reinforce their mutual understanding of what is Portfolio Manager Engagement also helps ensure expected from both parties. that the Portfolio Manager’s fees are closely monitored and The Board encourages the remain competitive. Company’s Portfolio Manager to engage with companies and in Gaining a deeper understanding doing so expects ESG issues to of the portfolio companies and be an important consideration. their strategies as well as incorporating consideration of The Board receives an update on ESG factors into the Frostrow’s engagement investment process assists in activities by way of a understanding and mitigating dedicated report at Board risks of an investment as well meetings and at other times as identifying future during the year as required. potential opportunities. The Board and Frostrow, acting in its capacity as AIFM, engage regularly with other service providers both in one-to-one meetings and via regular written reporting. This regular The Company contracts with interaction provides an third parties for other environment where topics, services including: custody, issues and business development company secretarial, needs can be dealt with accounting & administration efficiently and collegiately. and registrar. The Company ensures that the third parties The Board together with Service Providers to whom the services have been Frostrow also carried out a outsourced complete their review of the service roles in line with their providers’ business continuity service level agreements plans and additional cyber thereby supporting the Company security provisions. in its success and ensuring compliance with its The review of the performance obligations. of the Portfolio Manager and Frostrow is a continuous process carried out by the Board and the Management Engagement & Remuneration Committee with a formal evaluation being undertaken annually.
What were the key areas of engagement? What actions were taken, including main decisions? Key areas of engagement with the Portfolio Manager on an ongoing basis are portfolio composition, performance, outlook and business updates. • The Board engaged with the Portfolio • Regular review of the performance and Management team to discuss the Company’s make-up of the investment portfolio. overall performance as well as developments in individual portfolio • The integration of ESG factors into companies and wider macroeconomic the Portfolio Manager’s investment developments. processes. • The Portfolio Manager reports on ESG issues at each Board meeting. Key areas of engagement with Service Providers • The Directors have frequent • No specific action required as the engagement with the Company’s other reviews of the Company’s service service providers through the annual providers, have been positive and the cycle of reporting. This engagement is Directors believe their continued completed with the aim of maintaining appointment is in the best interests of an effective working relationship and the Company. oversight of the services provided. Key areas of engagement with the broker • Throughout the year the Board closely monitored the Company’s discount/premium • The Board is cognisant that the to NAV per share and received regular trading of the Company‘s shares at a updates from the broker. 80,265,298 persistent and significant discount or shares were bought back during the year, premium to the prevailing NAV per share and a further 10,677,869 shares were is not in the interests of bought back since the year-end to 5 June shareholders. 2024. No new shares were issued during the year, nor following the year-end to5 June 2024 . (Please see the Statement from the Chair for further information.)
PERFORMANCE AND FUTURE DEVELOPMENTS
A review of the Company’s year, its performance and the outlook for the Company can be found in the Chair’s Statement and in the Portfolio Manager’s Review.
The Company’s overall strategy remains unchanged.
LOOKING TO THE FUTURE
The Board concentrates its attention on the Company’s investment performance and OrbiMed’s investment approach and on factors that may have an effect on this approach. Marketing reports are given to the Board at each board meeting by the AIFM which include how the Company will be promoted and details of planned communications with existing and potential shareholders. The Board is regularly updated by the AIFM on wider investment trust industry issues and discussions are held at each Board meeting concerning the Company’s future development and strategy.
A review of the Company’s year, its performance since the year-end and the outlook for the Company can be found in the Chair’s Statement and in the Portfolio Manager’s Review. It is expected that the Company’s Strategy will remain unchanged in the coming year.
ALTERNATIVE PERFORMANCE MEASURES
The Financial Statements set out the required statutory reporting measures of the Company’s financial performance. In addition, the Board assesses the Company’s performance against a range of criteria which are viewed as particularly relevant for investment trusts, which are explained in greater detail in the Strategic Report, under the heading ‘Key Performance Indicators’.
By order of the Board
Company Secretary
REPORT OF THE DIRECTORS
The Directors present their Annual Report on the affairs of the Company together with the audited financial statements and the Independent Auditors’ Report for the year ended
SIGNIFICANT AGREEMENTS
Details of the services provided under these agreements are included in the Strategic Report.
Alternative investment fund management agreement
Frostrow is the designated AIFM for the Company on the terms and subject to the conditions of the alternative investment fund management agreement between the Company and Frostrow (the “AIFM Agreement”).
The notice period on the AIFM Agreement with Frostrow is 12 months, termination can be initiated by either party.
Details of the fee payable to Frostrow can be found in the Business Review.
Portfolio management agreement
Under the AIFM Agreement Frostrow has delegated the portfolio management function to OrbiMed, under a portfolio management agreement between it, the Company and Frostrow (the “Portfolio Management Agreement”).
OrbiMed receives a periodic fee equal to 0.65% p.a. of the Company’s NAV and a performance fee as set out in the Performance Fee section below. Its agreement with the Company may be terminated by either party giving notice of not less than 12 months.
Performance fee
Dependent on the level of long-term outperformance of the Company, OrbiMed is entitled to a performance fee. The performance fee is calculated by reference to the amount by which the Company’s NAV performance has outperformed the Benchmark (see inside front cover for details of the Benchmark).
The fee is calculated quarterly by comparing the cumulative performance of the Company’s NAV with the cumulative performance of the Benchmark since the launch of the Company in 1995. The performance fee amounts to 15.0% of any outperformance over the Benchmark. Provision is made within the daily NAV per share calculation as required and in accordance with generally accepted accounting standards.
In order to ensure that only sustained outperformance is rewarded, at each quarterly calculation date any performance fee payable is based on the lower of:
(i) The cumulative outperformance of the portfolio over the Benchmark as at the quarter end date; and
(ii) The cumulative outperformance of the portfolio over the Benchmark as at the corresponding quarter end date in the previous year
less any cumulative outperformance on which a performance fee has already been paid.
The effect of this is that outperformance has to be maintained for a twelve month period before it is paid.
As at
Depositary agreement
The Company appointed
Under the terms of the Depositary Agreement the Company has agreed to pay the Depositary a fee calculated at 1.75bp on net assets up to £150 million, 1.50 bps on net assets between £150 million and £300 million, 1.00bps on net assets between £300 million and £500 million and 0.50bps on net assets above £500 million.
The Depositary has delegated the custody and safekeeping of the Company’s assets to
The Delegation Agreement transfers the Depositary’s liability for the loss of the Company’s financial instruments held in custody by the Custodian and Prime Broker to the Custodian and Prime Broker as permitted by the AIFMD. The Company has consented to the transfer and reuse of its assets by the Custodian and Prime Broker (known as “rehypothecation”) in accordance with the terms of an institutional account agreement between the Company, the Custodian and Prime Broker and certain other J.P. Morgan entities (as defined therein).
Prime brokerage agreement
The Company appointed
The Custodian and Prime Broker is a registered broker
-
dealer and is regulated by the
RESULTS AND DIVIDENDS
The results attributable to shareholders for the year and the transfer to reserves are shown in the Income Statement and the Statement of Changes in Equity Details of the Company’s dividend record can be found in the Strategic Report.
Substantial interests in share capital
The Company was aware of the following substantial interests in the voting rights of the Company:
30 April 2024 31 March 2024 % of issued % of issued Number of Number of Shareholder share share shares shares capital capital Rathbone Brothers plc 48,038,882 8.88 48,436,836 8.85 Investec Wealth & Investment 41,413,773 7.66 42,232,373 7.72 Limited Interactive Investor 37,594,401 6.95 37,766,720 6.90 Hargreaves Lansdown plc 31,735,426 5.87 32,444,732 5.93 Charles Stanley & Co Limited 27,085,383 5.01 27,284,055 4.99 Forsyth Barr 20,859,186 3.86 21,376,017 3.91 Craigs Investment Partners 19,540,173 3.61 19,672,830 3.60 Evelyn Partners 19,239,555 3.56 19,450,805 3.56 Quilter Cheviot Investment 18,204,177 3.37 18,651,596 3.41 Management RBC Brewin Dolphin 18,758,151 3.47 18,495,921 3.38
As at
CAPITAL STRUCTURE
The Company’s capital structure comprises solely ordinary shares.
Share split
The price of the Company’s shares has increased substantially over the last 10 years. To assist monthly savers, those
During the year, and to
Voting rights in the Company’s shares
Details of the voting rights in the Company’s shares at the date of this Annual Report are given in note 9 to the Notice of Annual General Meeting. Each shareholder is entitled to one vote on a show of hands and, on a poll, one vote for every share held.
DIRECTORS’ & OFFICERS’ LIABILITY INSURANCE COVER
Directors’ & officers’ liability insurance cover was maintained by the Company during the year ended
DIRECTORS’ INDEMNITIES
During the year under review and to the date of this report, indemnities were in force between the Company and each of its Directors under which the Company has agreed to indemnify each Director, to the extent permitted by law, in respect of certain liabilities incurred as a result of carrying out his or her role as a Director of the Company. The Directors are also indemnified against the costs of defending any criminal or civil proceedings or any claim by the Company or a regulator as they are incurred provided that where the defence is unsuccessful the Director must repay those defence costs to the Company. The indemnities are qualifying third party indemnity provisions for the purposes of the Companies Act 2006.
A copy of each deed of indemnity is available for inspection at the Company’s registered office during normal business hours and will be available for inspection at the Annual General Meeting. Please refer to the Statement from the Chair for details of this year’s Annual General Meeting arrangements.
POLITICAL AND CHARITABLE DONATIONS
The Company has not in the past and does not intend in the future to make political or charitable donations.
MODERN SLAVERY ACT 2015
The Company does not provide goods or services in the normal course of business, and as a financial investment vehicle does not have customers. The Directors do not therefore consider that the Company is required to make a statement under the Modern Slavery Act 2015 in relation to slavery or human trafficking.
ANTI-BRIBERY AND CORRUPTION POLICY
The Board has adopted a zero tolerance approach to instances of bribery and corruption. Accordingly, it expressly prohibits any Director or associated persons when acting on behalf of the Company, from accepting, soliciting, paying, offering or promising to pay or authorise any payment, public or private in the
The Board ensures that its service providers apply the same standards in their activities for the Company.
A copy of the Company’s Anti Bribery and Corruption Policy can be found on its website at www.worldwidewh.com. The policy is reviewed regularly by the
CRIMINAL FINANCES ACT 2017
The Company has a commitment to zero tolerance towards the criminal facilitation of tax evasion.
A copy of the Company’s Prevention of the Facilitation of Tax Evasion Policy can be found on its website at www.worldwidewh.com. The policy is reviewed regularly by the
GLOBAL GREENHOUSE GAS EMISSIONS
The Company has no greenhouse gas emissions to report from its operations, nor does it have responsibility for any other emissions producing sources under the Companies Act 2006 (Strategic Reports and Directors’ Reports) Regulations 2013 or the Companies (Directors’ Report) and Limited Liability Partnerships (Energy and Carbon Report) Regulations 2018, including those within the Company’s underlying investment portfolio. Consequently, the Company consumed less than 40,000 kWh of energy during the year in respect of which the Report of the Directors is prepared and therefore is exempt from the disclosures required under the Streamlined Energy and Carbon Reporting criteria.
COMMON REPORTING STANDARD (“CRS”)
CRS is a global standard for the automatic exchange of information commissioned by the
Amendments of the Company’s Articles of Association require a special resolution to be passed by shareholders.
REQUIREMENTS OF THE LISTING RULES
Listing Rule 9.8.4 requires the Company to include certain information in a single identifiable section of the Annual Report or a cross reference table indicating where the information is set out. The Directors confirm that there are no disclosures to be made under Listing Rule 9.8.4.
The Board has made due diligence enquiries of the service providers that process the Company’s shareholder data, to ensure the Company’s compliance with the
By order of the Board
Company Secretary
STATEMENT OF DIRECTORS’ RESPONSIBILITIES
The Directors are responsible for preparing the Annual Report and the Financial Statements in accordance with applicable law and regulations. In preparing these financial statements, the Directors are required to:
· select suitable accounting policies and apply them consistently;
· make judgements and estimates that are reasonable and prudent;
·
follow applicable
· prepare the financial statements on a going concern basis unless it is inappropriate to presume that the Company will continue in business; and
· prepare a director’s report, a strategic report and a directors’ remuneration report which comply with the requirements of the Companies Act 2006.
The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company’s transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements and the Directors’ Remuneration Report comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Directors are responsible for ensuring that the Report of the Directors and other information included in the Annual Report is prepared in accordance with company law in the
The Directors are also responsible for ensuring that the Annual Report and the Financial Statements are made available on a website. The Annual Report and the Financial Statements are published on the Company’s website at www.worldwidewh.com and via Frostrow’s website at www.frostrow.com. The maintenance and integrity of
these websites, so far as it relates to the Company, is the responsibility of Frostrow. The work carried out by the Auditors does not involve consideration of the maintenance and integrity of these websites and, accordingly, the Auditors accept no responsibility for any changes that have occurred to the financial statements since they were initially presented on these websites. Visitors to the websites need to be aware that legislation in the
DISCLOSURE OF INFORMATION TO THE AUDITORS
So far as the Directors are aware, there is no relevant information of which the Auditors are unaware. The Directors have taken all steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the Auditors are aware of such information.
RESPONSIBILITY STATEMENT OF THE DIRECTORS IN RESPECT OF THE ANNUAL FINANCIAL REPORT
The Directors confirm to the best of their knowledge that:
·
the Annual Report and the Financial Statements have been prepared in accordance with applicable accounting standards, give a true and fair view of the assets, liabilities, financial position and the return for the year ended 31
· the Chairman’s Statement, Strategic Report and the Report of the Directors include a fair review of the information required by 4.1.8R to 4.1.11R of the FCA’s Disclosure Guidance and Transparency Rules; and
· the Annual Report and the Financial Statements, includes a fair review of the development and performance of the Company and of its financial position, together with a description of the principal risks and uncertainties it faces. Also, that taken as a whole they are fair, balanced and understandable and provide the information necessary to assess the Company’s performance, business model and strategy.
On behalf of the Board
Chair
CORPORATE GOVERNANCE
THE BOARD AND COMMITTEES
Responsibility for effective governance lies with the Board. The governance framework of the Company reflects the fact that as an investment company it has no employees and outsources portfolio management to OrbiMed and risk management, company management, company secretarial, administrative and marketing services to Frostrow.
THE BOARD Chair–Doug McCutcheon Senior Independent Director– Dr.Bina Rawal Five additional non-executive Directors, all considered independent, except forSven Borho . Key responsibilities: -- to provide leadership and set strategy, values and standards within a framework of prudent effective controls which enable risk to be assessed and managed; -- to ensure that a robust corporate governance framework is implemented; and -- to challenge constructively and scrutinise performance of all outsourced activities. Audit & Risk Committee Management Engagement & Chair Remuneration Committee Tim Livett* Chair All Independent Directors (excluding the Chair, Jo Parfrey Doug McCutcheon) Nominations Committee All Independent Directors Key responsibilities: Chair Key responsibilities: -- to review the Dr. Bina Rawal Company’s -- to review financial All Independent Directors regularly the reports; contracts, the -- to oversee the Key responsibilities: performance and risk and control remuneration of environment and -- to review the Company’s financial regularly the principal service reporting; and Board’s structure providers; -- to have primary and composition; -- to set the responsibility and Directors’ for the -- to make Remuneration relationship with recommendations Policy; and the Company’s for any changes or -- to review the external new appointments. terms and Auditors, to conditions of the review their Directors’ independence and appointments. performance, and to determine their remuneration.
*
The Board believes that
Copies of the full terms of reference, which clearly define the responsibilities of each Committee, can be obtained from the Company Secretary and can be found at the Company’s website at www.worldwidewh.com. Copies will also be available for inspection on the day of the Annual General Meeting.
CORPORATE GOVERNANCE STATEMENT
The Board is committed to maintaining and demonstrating high standards of corporate governance. The Board has considered the principles and recommendations of the AIC Code of Corporate Governance published in
The
The Board considers that reporting in accordance with the principles and recommendations of the AIC Code (which has been endorsed by the
The Company has complied with the principles and recommendations of the AIC Code.
The AIC Code can be viewed at www.theaic.co.uk and the
BOARD LEADERSHIP AND PURPOSE
Purpose and strategy
The purpose and strategy of the Company are described in the Strategic Report.
THE BOARD
The Board is responsible for the effective Stewardship of the Company’s affairs. Strategy issues and all operational matters of a material nature are considered at its meetings.
The Board consists of six non-executive Directors, each of whom, with the exception of
The Board carefully considers the various guidelines for determining the independence of non-executive Directors, placing particular weight on the view that independence is evidenced by an individual being independent of mind, character and judgement. All Directors retire at the AGM each year and, if appropriate, seek election or re - election. Each Director has signed a letter of appointment to formalise the terms of their engagement as a non - executive Director, copies of which are available on request at Frostrow’s offices.
BOARD CULTURE
The Board aims to consider and discuss differences of opinion, unique vantage points and to exploit fully areas of expertise. The Chair encourages open debate to foster a supportive and co-operative approach for all participants. Strategic decisions are discussed openly and constructively. The Board aims to be open and transparent with shareholders and other stakeholders and for the Company to conduct itself responsibly, ethically and fairly in its relationships with service providers.
The Board has gained assurance on whistleblowing procedures at the Company’s principal service providers to ensure employees at those companies are supported in speaking up and raising concerns. No concerns relating to the Company were raised during the year.
Shareholder relations
The Company has appointed Frostrow to provide marketing and investor relations services, in the belief that a well marketed investment company is more likely to grow over time, have a more diverse, stable list of shareholders and its shares will trade at close to net asset value per share over the long run. Frostrow actively promotes the Company as set out in the Strategic Report.
Shareholder communications
The Board, the AIFM and the Portfolio Manager consider maintaining good communications with shareholders and engaging with larger shareholders through meetings and presentations a key priority. Shareholders are kept informed by the publication of annual and half-year reports which include financial statements. These reports are supplemented by the daily release of the net asset value per share to the
The Board monitors the share register of the Company; it also reviews correspondence from shareholders at each meeting and maintains regular contact with major shareholders. Shareholders
The Board supports the principle that the Annual General Meeting be used to communicate with private investors, in particular. Shareholders are encouraged to attend the AGM, where they are given the opportunity to question the Chair, the Board and representatives of the Portfolio Manager. In addition, the Portfolio Manager makes a presentation to shareholders covering the investment performance and strategy of the Company at the AGM. Voting at the AGM is conducted on a poll and details of the proxy votes received in respect of each resolution will be made available on the Company’s website.
Significant holdings and voting rights
Details of the shareholders with substantial interests in the Company’s shares, the Directors’ authorities to issue and repurchase the Company’s shares, and the voting rights of the shares are set out in the Directors’ Report.
BOARD MEETINGS
The Board meets formally at least four times each year. A representative of OrbiMed attends all meetings; representatives from Frostrow are also in attendance at each Board meeting. The Independent Directors also meet before each formal Board meeting without representatives from Frostrow and OrbiMed being present. The Chair encourages open debate to foster a supportive and co - operative approach for all participants.
The Board has agreed a schedule of matters specifically reserved for decision by the Board. This includes establishing the investment objectives, strategy and the Benchmark, the permitted types or categories of investments, the markets in which transactions may be undertaken, the amount or proportion of the assets that may be invested in any geography or category of investment or in any one investment, and the Company’s share issuance and share buyback policies.
The Board, at its regular meetings, undertakes reviews of key investment and financial data, revenue projections and expenses, analyses of asset allocation, transactions and performance comparisons, share price and net asset value performance, marketing and shareholder communication strategies, the risks associated with pursuing the investment strategy, peer group information and industry issues.
The Chair is responsible for ensuring that the Board receives accurate, timely and clear information. Representatives of
The Board is responsible for strategy and has established an annual programme of agenda items under which it reviews the objectives and strategy for the Company at each meeting.
CONFLICTS OF INTEREST
Company Directors have a statutory obligation to avoid a situation in which they (and connected persons) have, or can have, a direct or indirect interest that conflicts, or may possibly conflict, with the interests of the Company. The Board has in place procedures for managing any actual or potential conflicts of interest. No conflicts of interest arose during the year under review.
BOARD FOCUS AND RESPONSIBILITIES
With the day to day management of the Company outsourced to service providers the Board’s primary focus at each Board meeting is reviewing the investment performance and associated matters, such as, inter alia , future outlook and strategy, gearing, asset allocation, investor relations, marketing, and industry issues.
In line with its primary focus, the Board retains responsibility for all the key elements of the Company’s strategy and business model, including:
· the Investment Objective, Policy and Benchmark, incorporating the investment and derivative guidelines and limits, and changes to these;
· the maximum level of gearing and leverage the Company may employ;
· a review of performance against the Company’s KPIs;
· a review of the performance and continuing appointment of service providers; and
· the maintenance of an effective system of oversight, risk management and corporate governance.
The Investment Objective, Policy, and Benchmark, including the related limits and guidelines, are set out in the Strategic Report, along with details of the gearing and leverage levels allowed.
Details of the principal KPIs and further information on the principal service providers, their performance and continuing appointment, along with details of the principal risks, and how they are managed, are set out in the Strategic Report.
The Corporate Governance Report includes a statement of compliance with corporate governance codes and best practice, and the Business Review includes details of the internal control and risk management framework within which the Board operates.
BOARD COMPOSITION AND SUCCESSION
Succession planning
During the year, the Nominations Committee considered the structure of the Board, recognising the need for progressive refreshment. A plan for recruiting a Director to succeed
The Board has an approved succession planning policy to ensure that (i) there is a formal, rigorous and transparent procedure for the appointment of new Directors; and (ii) the Board is comprised of members
Policy on the tenure of the Board Chair and other Directors
All Directors seek election or re-election every year. The Board subscribes to the view that long-serving Directors should not necessarily be prevented from forming part of an independent majority. The Board considers that a Director’s tenure does not necessarily reduce his or her ability to act independently and will continue to assess each Director’s independence annually through a formal performance evaluation.
The tenure of each Director is not ordinarily expected to exceed nine years. However, the Board has agreed that the tenure of the Board Chair may be extended in order to facilitate the Board’s overall orderly succession. The Board believes that this more flexible approach to the tenure of the Chair is appropriate in the context of the regulatory rules that apply to investment companies, which ensure that the Board Chair remains independent after appointment, while being consistent with the need for regular refreshment and diversity.
The Board asked
Since then, good progress has been made toward the end goal of having a Board structure that will facilitate Director renewal on a more regular basis than has occurred historically. And the process continues – as stated in the Statement from the Chair,
Portfolio Manager Representative on the Board
The Company was founded in 1995 by our Portfolio Manager, OrbiMed. Since that time, the Company has performed strongly, producing a compound net asset value per share annual return of +14.4%, well above our Benchmark and making us the third best performing trust in the
Since our inception, a representative of OrbiMed has served as a Director of the Company. While less common in the investment trust sector today than when the Company was founded, the Board believes that the Company’s long-term performance and its shareholders have and will continue to benefit from this arrangement. The Board has also taken steps to avoid any potential conflicts of interest – the current OrbiMed representative,
Appointments to the Board
The Nominations Committee considers annually the skills possessed by the Board and identifies any skill shortages to be filled by new Directors.
The rules governing the appointment and replacement of Directors are set out in the Company’s articles of association and the aforementioned succession planning policy. Where the Board appoints a new Director during the year, that Director will stand for election by shareholders at the next AGM. Subject to there being no conflict of interest, all Directors are entitled to vote on candidates for the appointment of new Directors and on the recommendation for shareholders’ approval for the Directors seeking re-election at the AGM. When considering new appointments, the Board endeavours to ensure that it has the capabilities required to be effective and oversee the Company’s strategic priorities.
This will include an appropriate range, balance and diversity of skills, experience and knowledge. The Company is committed to ensuring that any vacancies arising are filled by the most qualified candidates.
Diversity policy
The Board supports the principle of Boardroom diversity, of which gender and ethnicity are two important aspects. The Company’s policy is that the Board and its committees should be comprised of directors with a diverse range of skills, knowledge and experience and that appointments should be made on merit against objective criteria, including diversity in its broadest sense.
The objective of the policy is to have a broad range of approaches, backgrounds, skills, knowledge and experience represented on the Board. To this end, achieving a diversity of perspectives and backgrounds on the Board will be a key consideration in any director search process. The Board encourages any recruitment agencies it engages to find a diverse range of candidates that meet the criteria agreed for each appointment and, from the shortlist, aims to ensure that a diverse range of candidates is brought forward for interview.
The Board will continue to give due regard to the new diversity targets in the Listing Rules set out below. The Board will not discriminate unfairly on the grounds of gender, ethnicity, age, sexual orientation, disability or socio-economic background when considering the appointment of a new Director. Candidates’ educational and professional backgrounds, their cognitive and personal strengths, are considered against the specification prepared for each appointment.
The Board has noted the FCA’s new Listing Rules which require companies to report against the following diversity targets:
a) At least 40% of individuals on the board are women;
b) At least one of the senior board positions is held by a woman; and
c) At least one individual on the board is from a minority ethnic background.
As an externally managed investment company, the Company does not have the positions of CEO or CFO and therefore, as permitted by the Listing Rules, it has not reported formally against the second target as it is not applicable. As shown in the tables below, the Company has met the third target but has not yet met the first target. The Board notes that the statistics will change when
In accordance with the Listing Rules, the Board has provided the following information in relation to its diversity as at the year end.
Number of Number of senior Board Percentage of positions on Members the Board the Board* Men 4 67% 2 Women 2 33% 1 Not specified/prefer not to say – – – Number of Number of senior Board Percentage of positions on Members the Board the Board* White British or other White (including 5 83% 2 minority-white groups) Mixed/Multiple Ethnic Groups – – – Asian/Asian British 1 17% 1 Black/African/Caribbean/Black British – – – Other ethnic group, including Arab – – – Not specified/ prefer not to say – – –
*
The format of the above tables is prescribed in the Listing Rules which define ‘senior positions on the Board’ as ‘CEO, CFO, SID and Chair’. However, as an externally managed investment trust, the Company has no executive management functions, including the roles of CEO and CFO, and the Company has therefore excluded columns relating to executive management. In the absence of the aforementioned roles, the Board considers the Chair of the
The information above was obtained by asking the Directors to indicate on an anonymous form, how they should be categorised for the purposes of the Listing Rules disclosures.
MEETING ATTENDANCE
The number of meetings held during the year of the Board and its Committees, and each Director’s attendance level, is shown below:
Management Audit & Risk Nominations Engagement & Type and number of meetings held in Board 2023/24 Committee Committee Remuneration (5) (3) (2) Committee (1) Sarah Bates* 2 1 1 1 Sven Borho^ 5 – – – Tim Livett 5 3 2 1 Humphrey van der Klugt 5 3 2 1 Doug McCutcheon~ 5 – 2 1 Jo Parfrey 5 3 2 1 Dr Bina Rawal 5 3 2 1
*
Retired from the Board on
^
~
Not a member of the
All of the serving Directors attended the Annual General Meeting held on
BOARD EVALUATION
During the year, an externally facilitated review of the Board its committees and individual Directors (including each Director’s independence) was carried out by
The evaluation concluded that the Board works in a collegiate, efficient and effective manner, and there were no material weaknesses or concerns identified. The Board is satisfied that the structure, mix of skills and operation of the Board, its committees, and individual Directors continue to be effective.
The Board pays close attention to the capacity of individual Directors to carry out their work on behalf of the Company. In recommending individual Directors to shareholders for re-election, it considered their other Board positions and their time commitments and is satisfied that each Director has the capacity to be fully engaged with the Company’s business. The Board has considered the position of all of the Directors as part of the evaluation process, and believes that it would be in the Company’s best interests to propose them for re
-
election (with the exception of
Having a senior OrbiMed representative on the Board dates back to the Company’s inception in 1995. The Board believes that there is great value in the current representative,
Dr
The Chair is pleased to report that following a formal performance evaluation, the Directors’ performance continues to be effective and they continue to demonstrate commitment to the role.
TRAINING AND ADVICE
New appointees to the Board are provided with a full induction programme. The programme covers the Company’s investment strategy, policies and practices. The Directors are also given key information on the Company’s regulatory and statutory requirements as they arise including information on the role of the Board, matters reserved for its decision, the terms of reference of the Board Committees, the Company’s corporate governance practices and procedures and the latest financial information. It is the Chair’s responsibility to ensure that the Directors have sufficient knowledge to fulfil their role and Directors are encouraged to participate in training courses where appropriate.
The Directors have access to the advice and services of a Company Secretary through its appointed representative which is responsible to the
There is an agreed procedure for Directors, in the furtherance of their duties, to take independent professional advice if necessary at the Company’s expense.
RISK MANAGEMENT AND INTERNAL CONTROLS
The Board has overall responsibility for the Company’s risk management and internal control systems and for reviewing their effectiveness. The Company applies the guidance published by the
BENEFICIAL OWNERS OF SHARES – INFORMATION RIGHTS
Beneficial owners of shares
The Company has adopted a nominee share code which is set out below.
The annual and half-year financial reports, and a monthly fact sheet are available to all shareholders. The Board, with the advice of Frostrow, reviews the format of the annual and half-year financial reports so as to ensure they are useful to all shareholders and others taking an interest in the Company. In accordance with best practice, the annual report, including the Notice of the Annual General Meeting, is sent to shareholders at least 20 working days before the meeting. Separate resolutions are proposed for substantive issues.
ANNUAL GENERAL MEETING
The following information to be considered at the forthcoming annual general meeting is important and requires your immediate attention.
If you are in any doubt about the action you should take, you should seek advice from your stock broker, bank manager, solicitor, accountant or other financial adviser authorised under the Financial Services and Markets Act 2000 (as amended). If you have sold or transferred all of your ordinary shares in the Company, you should pass this document, together with any other accompanying documents, including the form of proxy, at once to the purchaser or transferee, or to the stock broker, bank or other agent through whom the sale or transfer was effected, for onward transmission to the purchaser or transferee
The Company’s Annual General Meeting will be held at Saddlers’ Hall,
In particular, resolutions relating to the following items will be proposed at the forthcoming Annual General Meeting.
Resolution 11 Authority to allot shares
Resolution 12 Authority to disapply pre-emption rights
Resolution 13 Authority to sell shares held in treasury on a non pre-emptive basis
Resolution 14 Authority to buy-back shares
Resolution 15 Authority to hold General Meetings (other than the Annual General Meeting) on at least 14 clear days’ notice
Resolution 16 The continuance of the Company as an investment trust for a further period of five years
Resolutions 11 and 16 will be proposed as Ordinary Resolutions and resolutions 12 to 15 will be proposed as Special Resolutions.
The full text of the resolutions can be found in the Notice of Annual General Meeting.
EXERCISE OF VOTING POWERS
The Board and the AIFM have delegated authority to OrbiMed to vote the shares owned by the Company. The Board has instructed that OrbiMed submit votes for such shares wherever possible. This accords with current best practice whilst maintaining a primary focus on financial returns. OrbiMed may refer to the Board on any matters of a contentious nature. The Board has reviewed OrbiMed’s Voting Guidelines and is satisfied with their approach.
The Company does not retain voting rights on any shares that are held as collateral in connection with the overdraft facility provided by
NOMINEE SHARE CODE
Where shares are held in a nominee company name, the Company undertakes:
· to provide the nominee company with multiple copies of shareholder communications, so long as an indication of quantities has been provided in advance; and
· to allow investors holding shares through a nominee company to attend general meetings, provided the correct authority from the nominee company is available.
Nominee companies are encouraged to provide the necessary authority to underlying shareholders to attend the Company’s general meetings.
By order of the Board
Company Secretary
INCOME STATEMENT
FOR THE YEAR ENDED
2024 2023 Notes Revenue Capital Total Revenue Capital Total £’000 £’000 £’000 £’000 £’000 £’000 Gains on investments 9 – 213,794 213,794 – 10,388 10,388 Exchange losses on – (5,492) (5,492) – (18,302) (18,302) currency Income from 2 21,398 – 21,398 23,945 – 23,945 investments balances AIFM, portfolio management and 3 (813) (15,454) (16,267) (877) (16,657) (17,534) performance fees Other expenses 4 (1,294) – (1,294) (1,142) (22) (1,164) Net return/(loss) before finance charges 19,291 192,848 212,139 21,926 (24,593) (2,667) and taxation Finance costs 5 (406) (7,718) (8,124) (193) (3,658) (3,851) Net return/(loss) 18,885 185,130 204,015 21,733 (28,251) (6,518) before taxation Taxation 6 (2,853) – (2,853) (2,021) (248) (2,269) Net return/(loss) 16,032 185,130 201,162 19,712 (28,499) (8,787) after taxation Return/(loss) per 7 2.7p 31.7p 34.4p 3.0p (4.4)p (1.4)p share*
* Comparative period restated for the sub-division of each ordinary share into 10 new ordinary shares during the year.
The “Total” column of this statement is the Income Statement of the Company. The “Revenue” and “Capital” columns are supplementary to this and are prepared under guidance published by
All revenue and capital items in the above statement derive from continuing operations.
The Company has no recognised gains and losses other than those shown above and therefore no separate Statement of Total Comprehensive Income has been presented.
The accompanying notes are an integral part of these statements.
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED
Capital Share Total Share redemption premium Capital Revenue shareholders’ capital reserve account reserve reserve funds £’000 £’000 £’000 £’000 £’000 £’000 At 31 March 2023 16,265 8,341 841,599 1,261,025 23,491 2,150,721 Net return after – – – 185,130 16,032 201,162 taxation Final dividend paid in respect of year – – – – (14,709) (14,709) ended 31 March 2023 Interim dividend paid in respect of – – – – (3,998) (3,998) year ended 31 March 2024 Shares purchased for – – – (252,759) – (252,759) treasury Shares cancelled (1,223) 1,223 – – – – from treasury At 31 March 2024 15,042 9,564 841,599 1,193,396 20,816 2,080,417
FOR THE YEAR ENDED
Capital Share Total Share redemption premium Capital Revenue shareholders’ capital reserve account reserve reserve funds £’000 £’000 £’000 £’000 £’000 £’000 At 1 April 2022 16,385 8,221 841,599 1,381,038 20,990 2,268,233 Net (loss)/return – – – (28,499) 19,712 (8,787) after taxation Final dividend paid in respect of year – – – – (12,721) (12,721) ended 31 March 2022 Interim dividend paid in respect of – – – – (4,490) (4,490) year ended 31 March 2023 Shares purchased for – – – (91,514) – (91,514) treasury Shares cancelled (120) 120 – – – – from treasury At 31 March 2023 16,265 8,341 841,599 1,261,025 23,491 2,150,721
STATEMENT OF FINANCIAL POSITION
AS AT
2024 2023 Notes £’000 £’000 Fixed assets Investments 9 2,108,235 2,186,417 Derivative – OTC swaps 9 & 10 944 209 2,109,179 2,186,626 Current assets Debtors 11 10,232 4,376 Cash 73,797 58,925 84,029 63,301 Current liabilities Creditors: amounts falling due within one year 12 (100,373) (72,105) Derivative – OTC swaps 9 & 10 (12,418) (27,101) (112,791) (99,206) Net current liabilities (28,762) (35,905) Total net assets 2,080,417 2,150,721 Capital and reserves Share capital 13 15,042 16,265 Capital redemption reserve 9,564 8,341 Share premium account 841,599 841,599 Capital reserve 17 1,193,396 1,261,025 Revenue reserve 20,816 23,491 Total shareholders' funds 2,080,417 2,150,721 Net asset value per share* 14 381.1p 343.5p
* Comparative period restated for the sub-division of each ordinary share into 10 new ordinary shares during the year.
The financial statements were approved by the Board of Directors and authorised for issue on
Chair
The accompanying notes are an integral part of this statement.
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED
2024 2023 Notes £’000 £’000 Net cash inflow from operating activities 18 2,262 5,394 Purchases of investments and derivatives (975,783) (1,189,133) Sales of investments and derivatives 1,260,461 1,404,617 Realised loss on foreign exchange transactions (5,535) (18,240) Net cash inflow from investing activities 279,143 197,244 Shares repurchased 13 (252,760) (91,514) Equity dividends paid (18,707) (17,211) Interest paid (8,124) (3,851) Net cash outflow from financing activities (279,591) (112,576) Increase in net cash 1,814 90,062
Cash flows from operating activities include interest received of £3,219,000 (2023: £2,302,000) and dividends received of £17,463,000 (2023: £20,507,000).
RECONCILIATION OF NET CASH FLOW MOVEMENT TO MOVEMENT IN
2024 2023 £’000 £’000 Increase in net cash/debt resulting from cashflows 1,814 90,062 Gains/(Losses) on foreign currency cash and cash equivalents 44 (62) Movement in net cash/debt in the year 1,858 90,000 Net cash/(debt) at 1 April 2,997 (87,003) Net cash at 31 March 4,855 2,997
Net cash includes the bank overdraft of £68,942,000 (2023: £55,928,000) (see note 12) and cash as per the balance sheet of £73,797,000 (2023: £58,925,000).
The accompanying notes are an integral part of this statement.
NOTES TO THE FINANCIAL STATEMENTS
1. ACCOUNTING POLICIES
The principal accounting policies, all of which have been applied consistently throughout the year in the preparation of these financial statements, are set out below:
(A) Basis of preparation
These financial statements have been prepared in accordance with the Companies Act 2006, FRS 102 ‘The Financial Reporting Standard applicable in the
The Company’s financial statements are presented in sterling, being the functional and presentational currency of the Company. All values are rounded to the nearest thousand pounds (£’000) except where otherwise indicated.
In addition, investments and derivatives held at fair value are categorised into a fair value hierarchy based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:
· Level 1 – Quoted prices in active markets.
· Level 2 – Inputs other than quoted prices included within Level 1 that are observable (i.e. developed using market data), either directly or indirectly.
· Level 3 – Inputs are unobservable (i.e. for which market data is unavailable).
Presentation of the Income Statement
In order to reflect better the activities of an investment trust company and in accordance with the SORP, supplementary information which analyses the Income Statement between items of a revenue and capital nature has been presented alongside the Income Statement. The net revenue return is the measure the Directors believe appropriate in assessing the Company’s compliance with certain requirements set out in Sections 1158 and 1159 of the Corporation Tax Act 2010.
Critical Accounting Judgements and Key Sources of Estimation Uncertainty
Critical accounting judgements and key sources of estimation uncertainty used in preparing the financial information are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable. The resulting estimates will, by definition, seldom equal the related actual results.
In the course of preparing the financial statements, the only key source of estimation uncertainty in the process of applying the Company’s accounting policies, is in relation to the valuation of the unquoted (Level 3) investments. The nature of estimation means that the actual outcomes could differ from those estimates, possibly significantly. The estimates relate to the investments where there is no appropriate market price i.e. the private investments. Whilst the board considers the methodologies and assumptions adopted in the valuation are supportable, reasonable and robust, because of the inherent uncertainty of valuation, those estimated values may differ significantly from the values that would have been used had a ready market for the investment existed. As at
Unquoted investments are all valued in line with the accounting policy set out below.
(B) Investments
Investments are measured under FRS 102 and are measured initially, and at subsequent reporting dates, at fair value. Investments are recognised and de-recognised at trade date where a purchase or sale is under a contract whose terms require delivery within the time frame established by the market concerned. Changes in fair value and gains or losses on disposal are included in the Income Statement as a capital item.
For quoted securities fair value is either bid price or last traded price, depending on the convention of the exchange on which the investment is listed.
Fair value is the price for which an asset could be exchanged between knowledgeable, willing parties in an arm’s length transaction. In estimating the fair value of unquoted investments, the AIFM and Board apply valuation techniques which are appropriate in light of the nature, facts and circumstances of the investment, and use reasonable current market data and inputs combined with judgement and assumptions and apply these consistently. The following principles used in determining the valuation of unquoted investments, are consistent with the International Private Equity and Venture Capital Valuation (“IPEV”) Guidelines. The assumptions and estimates made in determining the fair value of each unquoted investment are considered at least each six months or sooner if there is a triggering event. An example of where a valuation would be considered out of the six-month cycle is the success or failure of a drug under development to meet an anticipated outcome of its trial, announcement of the company undergoing an initial public offering, or other performance against tangible development milestones.
The primary valuation method applied in the valuation of the unquoted investments is the probability-weighted expected return method (“PWERM”), which considers on a probability weighted basis the future outcomes for the investment. When using the PWERM method significant judgements are made in estimating the various inputs into the model and recognising the sensitivity of such estimates. Examples of the factors where significant judgement is made include, but are not limited to, the probability assigned to potential future outcomes; discount rates; and, the likely exit scenarios for the investor company, for example, IPO or trade sale.
Where the investment being valued was itself made recently, or there has been a third party transaction in the investment, the price of the transaction may provide a good indication of fair value. Using the Price of
When using the price of a recent transaction in the valuations the Company looks to ‘re-calibrate’ this price at each valuation point by reviewing progress within the investment, comparing against the initial investment thesis, assessing if there are any significant events or milestones that would indicate the value of the investment value has changed materially and considering whether an alternative methodology would be more appropriate.
(C) Derivative financial instruments
The Company uses derivative financial instruments (namely put and call options and equity swaps).
All derivative instruments are valued initially, and at subsequent reporting dates, at fair value in the Statement of Financial Position.
The equity swaps are accounted for as Fixed Assets or Current Liabilities.
All gains and losses on over-the-counter (OTC) equity swaps are accounted for as gains or losses on investments. Where there has been a re-positioning of the swap, gains and losses are accounted for on a realised basis. All such gains and losses have been debited or credited to the capital column of the Income Statement.
Cash collateral held by counterparties is included within cash, except where there is a right of offset against the overdraft facility.
(D) Investment income
Dividends receivable are recognised on the ex-dividend date. Where no ex-dividend date is quoted, dividends are recognised when the Company’s right to receive payment is established. Foreign dividends are grossed up at the appropriate rate of withholding tax, with the withholding tax recognised in the taxation charge.
Income from fixed interest securities is recognised on a time apportionment basis so as to reflect the effective interest rate. Deposit interest is accounted for on an accruals basis.
(E) Expenses
All expenses are accounted for on an accruals basis. Expenses are charged through the revenue column of the Income Statement except as follows:
· expenses which are incidental to the acquisition or disposal of an investment are charged to the capital column of the Income Statement; and
· expenses are charged to the capital column of the Income Statement where a connection with the maintenance or enhancement of the value of the investments can be demonstrated. In this respect the portfolio management and AIFM fees have been charged to the Income Statement in line with the Board’s expected long-term split of returns, in the form of capital gains and income, from the Company’s portfolio. As a result, 5% of the portfolio management and AIFM fees are charged to the revenue column of the Income Statement and 95% are charged to the capital column of the Income Statement.
Any performance fee is charged in full to the capital column of the Income Statement.
(F) Finance costs
Finance costs are accounted for on an accruals basis. Finance costs are charged to the Income Statement in line with the Board’s expected long-term split of returns, in the form of capital gains and income, from the Company’s portfolio. As a result 5% of the finance costs are charged to the revenue column of the Income Statement and 95% are charged to the capital column of the Income Statement. Finance charges are accounted for on an accruals basis in the Income Statement using the effective interest rate method and are added to the carrying amount of the instrument to the extent that they are not settled in the period in which they arise.
(G) Taxation
The tax effect of different items of expenditure is allocated between capital and revenue using the marginal basis.
Deferred taxation is provided on all timing differences that have originated but not been reversed by the Statement of Financial Position date other than those differences regarded as permanent. This is subject to deferred tax assets only being recognised when it is probable that there will be suitable profits from which the reversal of timing differences can be deducted. Any liability to deferred tax is provided for at the rate of tax enacted or substantially enacted.
(H) Foreign currency
Transactions recorded in overseas currencies during the year are translated into sterling at the appropriate daily exchange rates. Assets and liabilities denominated in overseas currencies at the Statement of Financial Position date are translated into sterling at the exchange rates ruling at that date.
Exchange gains/losses on foreign currency balances
Any gains or losses on the translation of foreign currency balances, including the foreign currency overdraft, whether realised or unrealised, are taken to the capital or the revenue column of the Income Statement, depending on whether the gain or loss is of a capital or revenue nature.
(I) Capital redemption reserve
This reserve arose when ordinary shares were redeemed by the Company and subsequently cancelled. When ordinary shares are redeemed by the Company and subsequently cancelled, an amount equal to the par value of the ordinary share capital is transferred from the ordinary share capital to the capital redemption reserve.
(
The following are transferred to this reserve:
· gains and losses on the disposal of investments;
· exchange differences of a capital nature, including the effects of changes in exchange rates on foreign currency borrowings;
· expenses, together with the related taxation effect, in accordance with the above policies; and
· changes in the fair value of investments and derivatives.
This reserve can be used to distribute realised capital profits by way of dividend or share buybacks. Any gains in the fair value of investments that are not readily convertible to cash are treated as unrealised gains in the capital reserve. Distributions are only payable out of the capital reserve if capital reserves are greater than the proposed distribution and positive on the date of distribution.
(K) Revenue reserve
The revenue reserve is distributable by way of dividend. Dividends are only payable out of the revenue reserve if revenue reserves are greater than the proposed dividend and positive on the date of distribution.
(L) Dividend payments
Dividends paid by the Company on its shares are recognised in the financial statements in the year in which they become payable and are shown in the Statement of Changes in Equity.
(M) Cash and cash equivalents
Cash comprises cash at bank and cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.
Bank overdrafts are considered as a component of cash and cash equivalents as they are repayable on demand and form an integral part of the Company’s cash management.
2. INCOME FROM INVESTMENTS
2024 2023 £’000 £’000 Income from investments Overseas dividends 14,699 18,431 Fixed interest income – 184 UK dividends 3,480 3,212 18,179 21,827 Other income Derivatives 27 79 Deposit interest 3,192 2,039 Total income from investments 21,398 23,945 Total income comprises: Dividends 18,179 21,643 Interest 3,219 2,302 21,398 23,945
3. AIFM, PORTFOLIO MANAGEMENT AND PERFORMANCE FEES
2024 2023 Revenue Capital Total Revenue Capital Total £’000 £’000 £’000 £’000 £’000 £’000 AIFM fee 141 2,689 2,830 151 2,862 3,013 Portfolio management fee 672 12,765 13,437 726 13,795 14,521 813 15,454 16,267 877 16,657 17,534
Further details on the above fees are set out in the Strategic Report and in the Report of the Directors.
4. OTHER EXPENSES
2024 2023 £’000 £’000 Directors’ remuneration 211 212 Employer’s NIC on Directors’ remuneration 17 18 Auditors’ remuneration for the audit of the Company’s financial 56 54 statements Depositary and custody fees 227 208 Listing fees 101 85 Registrar fees 58 45 Legal and professional costs 267 181 Broker fees – (15) Other costs 357 354 1,294 1,142 Professional fees (Capital)^ – 22 1,294 1,164
Details of the amounts paid to Directors are included in the Directors’ Remuneration Report.
^ Professional fees in respect of acquisition of unquoted investments. These fees do not form part of the ongoing charge ratio.
5. FINANCE COSTS
2024 2023 Revenue Capital Total Revenue Capital Total £’000 £’000 £’000 £’000 £’000 £’000 Finance costs 406 7,718 8,124 193 3,658 3,851
6. TAXATION
(A) Analysis of charge in year
2024 2023 Revenue Capital Total Revenue Capital Total £’000 £’000 £’000 £’000 £’000 £’000 Corporation tax at 25% (2023: 19%) – – – – – – Overseas taxation 2,853 – 2,853 2,021 248 2,269 2,853 – 2,853 2,021 248 2,269
(B) Factors affecting the tax charge for the year
Approved investment trusts are exempt from tax on capital gains made within the Company.
The tax charged for the year is lower (2023: higher) than the standard rate of corporation tax of 25% (2023: 19%).
The difference is explained below.
2024 2023 Revenue Capital Total Revenue Capital Total £’000 £’000 £’000 £’000 £’000 £’000 Net return/(loss) before 18,885 185,130 204,015 21,733 (28,251) (6,518) taxation Corporation tax at 25% (2023: 4,721 46,283 51,004 4,129 (5,415) (1,286) 19%) Non-taxable (gains)/losses on – (52,076) (52,076) – 1,551 1,551 investments Overseas withholding taxation 2,853 – 2,853 2,021 – 2,021 Overseas capital gains tax – – – – 248 248 Non taxable dividends (4,545) – (4,545) (4,112) – (4,112) Unutilised management (176) 5,056 4,880 (17) 3,864 3,847 expenses Corporate interest – 737 737 – – – restriction Total tax charge 2,853 – 2,853 2,021 248 2,269
(C) Provision for deferred tax
No provision for deferred taxation has been made in the current or prior year. The Company has not provided for deferred tax on capital profits and losses arising on the revaluation or disposal of investments, as it is exempt from tax on these items because of its status as an investment trust company.
The Company has not recognised a deferred tax asset of £54,349,000 (25% tax rate) (2023: £49,985,000 (25% tax rate)) as a result of excess management expenses and overdraft expenses. It is not anticipated that these excess expenses will be utilised in the foreseeable future.
7. RETURN/(LOSS) PER SHARE
2024 2023 £’000 £’000 The return/(loss) per share is based on the following figures: Revenue return 16,032 19,712 Capital return/(loss) 185,130 (28,499) 201,162 (8,787) Weighted average number of ordinary shares in issue 585,308,530 644,744,220 during the year Revenue return per ordinary share 2.7p 3.0p Capital return/(loss) per ordinary share 31.7p (4.4)p 34.4p (1.4)p
2023 return per share figures restated for the sub-division of each ordinary share into 10 new ordinary shares during the year.
The calculation of the total, revenue and capital (loss)/return per ordinary share is carried out in accordance with IAS 33, “Earnings per Share”, in accordance with the requirements of FRS 102.
8. DIVIDENDS
Under
2024 2023 £’000 £’000 Final dividend in respect of the year ended 31 March 2022 – 12,721 Interim dividend in respect of the year ended 31 March 2023 – 4,490 Final dividend in respect of the year ended 31 March 2023 14,709 – Interim dividend in respect of the year ended 31 March 2024 3,998 – 18,707 17,211
In respect of the year ended
2024 2023 £’000 £’000 Revenue available for distribution by way of dividend for the 16,032 19,712 year Interim dividend in respect of the year ended 31 March 2024 (3,998) – Final dividend in respect of the year ended 31 March 2024* (11,241) – Interim dividend in respect of the year ended 31 March 2023 – (4,490) Final dividend in respect of the year ended 31 March 2023 – (14,717) Net retained revenue 793 505
*
based on 535,264,463 shares in issue (excluding shares held in treasury) as at
9. INVESTMENTS AND DERIVATIVE FINANCIAL INSTRUMENTS
Derivative Financial Quoted Unquoted Instruments - Total Investments Investments Total Net Investments £’000 £’000 £’000 £’000 £’000 Cost at 1 April 1,829,033 121,703 1,950,736 – 1,950,736 2023 Investment holdings gains/ 212,214 23,467 235,681 (26,892) 208,789 (losses) at 1 April 2023 Valuation at 1 2,041,247 145,170 2,186,417 (26,892) 2,159,525 April 2023 Movement in the year: Purchases at cost 987,042 3,278 990,320 – 990,320 Sales - proceeds (1,244,565) – (1,244,565) (22,313) (1,266,878) Net movement in investment holding 191,384 (15,321) 176,063 37,731 213,794 gains/(losses) Valuation at 31 1,975,108 133,127 2,108,235 (11,474) 2,096,761 March 2024 Cost at 31 March 1,549,252 124,985 1,674,237 – 1,674,237 2024 Investment holding gains/(losses) at 425,856 8,142 433,998 (11,474) 422,524 31 March 2024 Valuation at 31 1,975,108 133,127 2,108,235 (11,474) 2,096,761 March 2024
* See Note 16.
The Company received £1,266,878,000 (2023: £1,393,875,000) from investments and derivatives sold in the year. The book cost of these was £1,266,824,000 (2023: £1,307,159,000). These investments and derivatives have been revalued over time and until they were sold any unrealised gains/losses were included in the fair value of the investments.
2024 2023 £’000 £’000 Net movement in investment holding gains in the year 176,063 33,331 Net movement in derivative holding gains/(losses) in the year 37,731 (22,835) Effective interest rate amortisation – (108) Gains on investments 213,794 10,388
Purchase transaction costs were £992,000 (2023: £1,660,000). Sales transaction costs were £1,299,000 (2023: £1,266,000). These comprise mainly commission and stamp duty.
10. DERIVATIVES
2024 2023 £’000 £’000 Fair value of OTC equity swaps (asset) 944 209 Fair value of OTC equity swaps (liability) (12,418) (27,101) (11,474) (26,892)
See note 9 above for movements during the year.
11. DEBTORS
2024 2023 £’000 £’000 Amounts due from brokers 6,508 88 Withholding taxation recoverable 1,665 2,882 Prepayments and accrued income 2,059 1,406 10,232 4,376
12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023 £’000 £’000 Amounts due to brokers 23,973 9,432 Overdraft drawn* 68,942 55,928 Other creditors and accruals 7,458 6,745 100,373 72,105
*
The Company’s borrowing requirements are met through the utilisation of an overdraft facility provided by
13. SHARE CAPITAL
2024 2023 Number Number As at 1 April 62,620,763 65,457,246 Purchase of shares into treasury pre-share split (2,507,439) (2,836,483) Issue of shares following 10 for 1 share split 541,019,916 – Purchase of shares into treasury post-share split (55,190,908) – As at year end: In circulation 545,942,332 62,620,763 In Treasury 55,722,868 2,438,015 Listed 601,665,200 65,058,778 Nominal Value of 2.5p (2023: 25p) ordinary shares 15,042 16,265 (£000)
During the year, the Company bought back ordinary shares at a cost of £252,759,000 (Year ended
Following the AGM held in
14. NET ASSET VALUE PER SHARE
2024 2023 Net asset value per share 381.1p 343.5p
The net asset value per share is based on the assets attributable to equity shareholders of £2,080,417,000 (2023: £2,150,721,000) and on the number of shares in issue at the year-end (excluding those shares held in treasury) of 545,942,332 (2023: 62,620,763) in issue. Comparative NAV per share adjusted to reflect ten for one share issue during the year).
15. RELATED PARTIES AND TRANSACTIONS WITH THE AIFM
The following are considered to be related parties:
·
·
· The Directors of the Company
Details of the remuneration of all Directors can be found in the Remuneration Report. Details of the Directors’ interests in the capital of the Company can also be found in the Remuneration Report.
Three current and two former partners at OrbiMed have a minority financial interest totalling 19.4% in Frostrow, the Company’s AIFM. Details of the fees paid to Frostrow by the Company can be found in note 3.
16. FINANCIAL INSTRUMENTS
Risk management policies and procedures
The Company’s financial instruments comprise securities and other investments, derivative instruments, cash balances, overdrafts and debtors and creditors that arise directly from its operations.
As an investment trust, the Company invests in equities and other investments for the long term so as to secure its investment objective. In pursuing its investment objective, the Company is exposed to a variety of risks that could result in a reduction in the Company’s net assets.
The main risks that the Company faces arising from its financial instruments are:
(i) market risk (including foreign currency risk, interest rate risk and other price risk)
(ii) liquidity risk
(iii) credit risk
These risks, with the exception of liquidity risk, and the Directors’ approach to the management of them have not changed from the previous accounting year. The AIFM, in close co-operation with the Board and the Portfolio Manager, co - ordinates the Company’s risk management.
Use of derivatives
Equity swaps are used within the Company’s portfolio.
OTC equity swaps
The Company uses OTC equity swap positions to gain access to the Indian and Chinese markets when it is more cost effective to gain access via swaps or to gain exposure to thematic baskets of stocks.
Offsetting disclosure
Swap trades and OTC derivatives are traded under ISDA† Master Agreements. The Company currently has such agreements in place with Goldman Sachs and JP Morgan.
These agreements create a right of set-off that becomes enforceable only following a specified event of default, or in other circumstances not expected to arise in the normal course of business. As the right of set-off is not unconditional, for financial reporting purposes, the Company does not offset derivative assets and derivative liabilities.
†
(i) Other price risk
In pursuance of the Company’s Investment Objective the Company’s portfolio, including its derivatives, is exposed to the risk of fluctuations in market prices and foreign exchange rates.
The Board manage these risks through the use of limits and guidelines, monthly compliance reports from Frostrow and reports from Frostrow and OrbiMed presented at each Board meeting.
Other price risk exposure
The Company’s gross exposure to other price risk is represented by the fair value of the investments and the underlying exposure through the derivative investments held at the year-end as shown in the table below.
2024 2023 Notional* Notional* Assets Liabilities exposure Assets Liabilities exposure £’000 £’000 £’000 £’000 £’000 £’000 Investments 2,108,235 – 2,108,235 2,186,417 – 2,186,417 OTC equity swaps 944 (12,418) 198,082 209 (27,101) 190,704 2,109,179 (12,418) 2,306,318 2,186,626 (27,101) 2,377,121
* The notional exposure is calculated in accordance with the AIFMD requirements for calculating exposure via derivatives. See glossary.
Other price risk sensitivity
If market prices of all of the Company’s financial instruments including the derivatives at the Statement of Financial Position date had been 25% higher or lower (2023: 25% higher or lower) while all other variables remained constant: the revenue return would have decreased/increased by £0.2 million (2023: £0.2 million); the capital return would have increased/decreased by £572.5 million (2023: £596.6 million); and, the return on equity would have increased/decreased by £572.3 million (2023: £594.6 million). The calculations are based on the portfolio as at the respective Statement of Financial Position dates and are not representative of the year as a whole.
(ii) Foreign currency risk
A significant proportion of the Company’s portfolio and derivative positions are denominated in currencies other than sterling (the Company’s functional currency, and the currency in which it reports its results). As a result, movements in exchange rates can significantly affect the sterling value of those items.
Foreign currency exposure
The fair values of the Company’s monetary assets and liabilities that are denominated in foreign currencies are shown below.
2024 2023 Current Current Current Current assets liabilities Investments assets liabilities Investments £’000 £’000 £’000 £’000 £’000 £’000 U.S. dollar 140,646 (166,711) 1,579,696 115,823 (124,286)1,488,321 Swiss franc 11,102 – 11,652 2,466 –84,999 Japanese yen 1,041 – 130,007 793 –135,398 Hong Kong dollar – – 62,058 – – 109,170 Other 993 – 132,435 194 – 201,798 153,782 (166,711) 1,915,848 119,276 (124,286) 2,019,686
Foreign currency sensitivity
The following table details the sensitivity of the Company’s net return for the year and shareholders’ funds to a 10% increase and decrease in sterling against the relevant currency (2023: 10% increase and decrease).
These percentages have been determined based on market volatility in exchange rates over the previous 12 months. The sensitivity analysis is based on the Company’s significant foreign currency exposures at each Statement of Financial Position date.
2024 2023 USD YEN CHF HKD USD YEN CHF HKD £’000 £’000 £’000 £’000 £’000 £’000 £’000 £’000 Sterling 195,910 14,561 2,528 6,895 188,606 15,132 9,718 12,130 depreciates Sterling (160,290) (11,913) (2,069) (5,642) (154,314) (12,381) (7,951) (9,925) appreciates
(iii) Interest rate risk
Interest rate changes may affect:
– the interest payable on the Company’s variable rate borrowings;
– the level of income receivable from floating and fixed rate securities and cash at bank and on deposit;
– the fair value of investments in fixed interest securities.
Interest rate exposure
The Company’s main exposure to interest rate risks is through its overdraft facility with
The interest rate exposure is shown in the table below.
2024 2023 Floating Floating rate rate £’000 £’000 Cash 78,721 100,366 Overdraft facility (12,412) (97,369) Financed swap positions (209,556) (217,596) (143,247) (214,599)
All interest rate exposures are held in
Cash of £78.7 million (2023: £100.4 million) was held as collateral against the financed swap positions, of which £4.9 million (2023: £41.4 million) was offset against the overdraft position.
Interest rate sensitivity
If interest rates had been 1% higher or lower and all other variables were held constant, the Company’s net return for the year ended
(iv) Liquidity risk
This is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities.
Management of the risk
Liquidity risk is not considered significant as the majority of the Company’s assets are investments in quoted securities that are readily realisable within one week, in normal market conditions. There may be circumstances where market liquidity is lower than normal. Stress tests have been performed to understand how long the portfolio would take to realise in such situations. The Board is comfortable that in such a situation the Company would be able to meet its liabilities as they fall due.
Liquidity exposure and maturity
Contractual maturities of the financial liability exposures as at
2024 2023 3 to 12 3 months 3 to 12 3 months months or less months or less £’000 £’000 £’000 £’000 Overdraft facility – 12,412 – 97,369 Amounts due to brokers and accruals – 31,461 – 16,177 OTC equity swaps 12,418 – 27,101 – 12,418 43,873 27,101 113,546
£4.9 million of cash held as collateral is offset against the overdraft facility in the Statement of Financial Position, as set out in Note 16(iii) above.
(v) Credit risk
Credit risk is the risk of failure of a counterparty to discharge its obligations resulting in the Company suffering a financial loss.
The carrying amounts of financial assets best represent the maximum credit risk at the Statement of Financial Position date.
The Company’s quoted securities are held on its behalf by
Certain of the Company’s assets can be held by
CREDIT RISK EXPOSURE
2024 2023 £’000 £’000 Derivative – OTC equity swaps 944 209 Current assets: Other receivables (amounts due from brokers, dividends and 10,232 4,376 interest receivable) Cash 73,797 58,925
(vi) Fair value of financial assets and financial liabilities
Financial assets and financial liabilities are either carried in the Statement of Financial Position at their fair value (investments and derivatives) or the Statement of Financial Position amount is a reasonable approximation of fair value (due from brokers, dividends and interest receivable, due to brokers, accrual, cash at bank, and the overdraft).
(vii) Hierarchy of investments
The Company has classified its financial assets designated at fair value through profit or loss and the fair value of derivative financial instruments using a fair value hierarchy that reflects the significance of the inputs used in making the fair value measurements. The hierarchy has the following levels:
· Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;
· Level 2 – inputs other than quoted prices included with Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
· Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).
Level 1 Level 2 Level 3 Total As of 31 March 2024 £’000 £’000 £’000 £’000 Investments held at fair value through 1,975,108 – 133, 127 2,108,235 profit or loss Derivatives: OTC swaps (assets) – 944 – 944 Derivatives: OTC swaps (liabilities) – (12,418) – (12,418) Financial instruments measured at fair 1,975,108 (11,474) 133,127 2,096,761 value
As at 31 March 2024 & 2023, ten equity investments and a deferred consideration investment have been classified as level 3. All level 3 positions have been valued in accordance with the accounting policy set out in Note 1(b).
During 2023 one unquoted investment was transferred to Level 1 following their initial public offering.
Level 1 Level 2 Level 3 Total As of 31 March 2023 £’000 £’000 £’000 £’000 Investments held at fair value through 2,041,247 – 145,170 2,186,417 profit or loss Derivatives: OTC swaps (assets) – 209 – 209 Derivatives: OTC swaps (liabilities) – (27,101) – (27,101) Financial instruments measured at fair 2,041,247 (26,892) 145,170 2,159,525 value
(viii) Capital management policies and procedures
The Company’s capital management objectives are to ensure that it will be able to continue as a going concern and to maximise the income and capital return to its equity shareholders through an appropriate level of gearing or leverage.
The Board’s policy on gearing and leverage is set out in the Strategic Report.
As at 31 March 2024 the Company had a net leverage percentage of 10.8% (2023: 10.5%).
The capital structure of the Company consists of the equity share capital, retained earnings and other reserves as shown in the Statement of Financial Position.
The Board, with the assistance of the AIFM and the Portfolio Manager, monitors and reviews the broad structure of the Company’s capital on an ongoing basis. This includes a review of:
– the planned level of gearing, which takes into account the Portfolio Manager’s view of the market;
– the need to buy back equity shares, either for cancellation or to hold in treasury, in light of any share price discount to net asset value per share in accordance with the Company’s share buy-back policy;
– the need for new issues of equity shares, including issues from treasury; and
– the extent to which revenue in excess of that which is required to be distributed should be retained.
The Company’s objectives, policies and processes for managing capital are unchanged from the preceding accounting year.
17. CAPITAL RESERVE
Capital Reserves Investment Holding Other Gains* Total £’000 £’000 £’000 At 1 April 2023 888,953 372,072 1,261,025 Net gains/(losses) on investments 60 213,734 213,794 Expenses and taxation charged to capital (23,172) – (23,172) Exchange loss on currency balances (5,492) – (5,492) Shares repurchased for Treasury (252,759) – (252,759) At 31 March 2024 607,590 585,806 1,193,396
* Investment holding gains relate to the revaluation of investments and derivatives held at the reporting date. (See note 9 for further details).
Under the Company’s Articles of Association, sums within “capital reserves – other” are also available for distribution.
18. RECONCILIATION OF OPERATING RETURN/(LOSS) TO NET CASH INFLOW FROM OPERATING ACTIVITIES
2024 2023 £’000 £’000 Gain/(loss) before finance charges and taxation 212,139 (2,667) Add: capital (gain)/loss before finance charges and taxation (192,848) 24,593 Revenue return before finance charges and taxation 19,291 21,926 Expenses charged to capital (15,454) (16,679) (Increase)/decrease in other debtors (653) 150 Increase in other creditors 714 2,669 Net taxation suffered on investment income (1,636) (2,564) Amortisation – (108) Net cash inflow from operating activities 2,262 5,394
GLOSSARY OF TERMS AND ALTERNATIVE PERFORMANCE MEASURES (“APMS”)
ALTERNATIVE INVESTMENT FUND MANAGERS DIRECTIVE (“AIFMD”)
Agreed by the
AIFMD classifies certain investment vehicles, including investment companies, as Alternative Investment Funds (AIFs) and requires them to appoint an Alternative Investment Fund Manager (AIFM) and a depositary to manage and oversee the operations of the investment vehicle. The Board of the Company retains responsibility for strategy, operations and compliance and the Directors retain a fiduciary duty to shareholders.
Alternative performance measure (“APM”)
An APM is a numerical measure of the Company’s current, historical or future financial performance, financial position or cash flows, other than a financial measure defined or specified in the applicable financial framework. In selecting these Alternative Performance Measures, the Directors considered the key objectives and expectations of typical investors in an investment trust such as the Company.
Discount or premium
A description of the difference between the share price and the net asset value per share. The size of the discount or premium is calculated by subtracting the share price from the net asset value per share and is usually expressed as a percentage (%) of the net asset value per share. If the share price is higher than the net asset value per share the result is a premium. If the share price is lower than the net asset value per share, the shares are trading at a discount.
Equity swaps
An equity swap is an agreement where one party (counterparty) transfers the total return of an underlying equity position to the other party (swap holder) in exchange for a payment of the principal, and interest for financed swaps, at a set date. Total return includes dividend income and gains or losses from market movements. The exposure of the holder is the market value of the underlying equity position.
The Company currently only uses financed equity swaps, where payment is made on maturity. Financed swaps increase exposure by the value of the underlying equity position, with no initial outlay and no increase in the investment portfolio’s value – there is therefore embedded leverage within a financed swap due to the deferral of payment to maturity.
The Company employs swaps for two purposes:
· To gain access to individual stocks in the Indian, Chinese and other emerging markets, where the Company is not locally registered to trade or is able to gain in a more cost efficient manner than holding the stocks directly; and,
· To gain exposure to thematic baskets of stocks (a Basket Swap). Basket Swaps are used to build exposure to themes, or ideas, that the Portfolio Manager believes the Company will benefit from and where holding a Basket Swap is more cost effective and operationally efficient than holding the underlying stocks or individual swaps.
Gearing
Gearing is calculated as the overdraft drawn, less net current assets (excluding dividends), divided by Net Assets, expressed as a percentage. For years prior to 2013, the calculation was based on borrowings as a percentage of Net Assets.
* Alternative Performance Measure
International swaps and derivatives association (“ISDA”)
ISDA has created a standardised contract (the ISDA Master Agreement) which sets out the basic trading terms between the counterparties to derivative contracts.
Leverage
Leverage is defined in the AIFMD as any method by which the AIFM increases the exposure of an AIF. In addition to the gearing limit the Company also has to comply with the AIFMD leverage requirements. For these purposes the Board has set a maximum leverage limit of 140% for both methods. This limit is expressed as a % with 100% representing no leverage or gearing in the Company. There are two methods of calculating leverage as follows:
The Gross Method is calculated as total exposure divided by Shareholders’ Funds. Total exposure is calculated as net assets, less cash and cash equivalents, adding back cash borrowing plus derivatives converted into the equivalent position in their underlying assets.
The Commitment Method is calculated as total exposure divided by Shareholders Funds. In this instance total exposure is calculated as net assets, less cash and cash equivalents, adding back cash borrowing plus derivatives converted into the equivalent position in their underlying assets, adjusted for netting and hedging arrangements.
See the definition of Equity Swaps for more details on how exposure through these instruments is calculated.
2024 2023 £’000 £’000 Fair Value Exposure* Fair Value Exposure* Investments 2,108,235 2,108,235 2,186,417 2,186,417 OTC equity swaps (11,474) 198,082 (26,092) 190,704 2,096,761 2,306,317 2,159,525 2,377,121 Shareholders’ funds 2,081,180 2,150,721 Leverage % 10.8% 10.5%
* Calculated in accordance with AIFMD requirements using the Commitment Method
MSCI World Health Care Index (the Company’s Benchmark)
The MSCI World Health Care Index is designed to capture the large and mid capitalisation segments across 23 developed markets countries: All securities in the index are classified as healthcare as per the Global Industry Classification Standard (GICS). Developed Markets countries include:
NAV per share (pence)
The value of the Company’s assets, principally investments made in other companies and cash being held, minus any liabilities. The NAV is also described as ‘shareholders’ funds’ per share. The NAV is often expressed in pence per share after being divided by the number of shares which have been issued. The NAV per share is unlikely to be the same as the share price which is the price at which the Company’s shares can be bought or sold by an investor. The share price is determined by the relationship between the demand and supply of the shares.
* Alternative Performance Measure
Net asset value (NAV) per share total return*
The theoretical total return on shareholders’ funds per share, reflecting the change in NAV assuming that dividends paid to shareholders were reinvested at NAV at the time the shares were quoted ex-dividend. A way of measuring investment management performance of investment trusts which is not affected by movements in discounts/premiums.
2024 2023 NAV Total Return p p Opening NAV 343.5 346.5 Increase/(decrease) in NAV 37.6 (3.1) Closing NAV 381.1 343.5 % increase/(decrease) in NAV 10.9% (0.9%) Impact of reinvested dividends 1.1% 0.8% NAV Total Return 12.0% (0.1%)
Ongoing Charges*
Ongoing charges are calculated by taking the Company’s annualised ongoing charges, excluding finance costs, taxation, performance fees and exceptional items, and expressing them as a percentage of the average daily net asset value of the Company over the year.
2024 2023 £’000 £’000 AIFM & Portfolio Management fees (Note 3) 16,267 17,534 Other Expenses – Revenue (Note 4) 1,294 1,142 Total Ongoing Charges 17,561 18,676 Performance fees paid/crystallised – – Total 17,561 18,676 Average net assets 2,036,653 2,247,296 Ongoing Charges 0.9% 0.8% Ongoing Charges (including performance fees paid or 0.9% 0.8% crystallised during the year)
Rehypothecation
Rehypothecation is the practice by banks and brokers of using, for their own purposes, assets that have been posted as collateral by clients.
Share Price Total Return*
Return to the investor on mid-market prices assuming that all dividends paid were reinvested.
2024 2023 Share Price Total Return p p Opening share price 311.5 327.5 Increase in share price 23.5 16.0 Closing share price 335.0 311.5 % increase in share price 7.5% (4.9%) Impact of reinvested dividends 1.1% 0.8% Share Price Total Return 8.6% (4.1%)
* Alternative Performance Measure
NOTICE OF THE ANNUAL GENERAL MEETING
Notice is hereby given that the Annual General Meeting of
Ordinary Resolutions
To consider and, if thought fit, pass the following resolutions which will be proposed as ordinary resolutions:
1. That the Report of the Directors and the audited Accounts for the year ended 31 March 2024 together with the Report of the Auditors thereon be received and adopted.
2. To approve the payment of a final dividend of 2.1p per ordinary share for the year ended 31 March 2024.
3. To approve the Company’s dividend policy, as set out on page 31 of the Annual Report for the year ended 31 March 2024.
4.
To re-elect Mr
5.
To re-elect Mr
6.
To re-elect Dr
7.
To re-elect Mr
8.
To re-elect Ms
9.
To re-appoint
10. To approve the Directors’ Remuneration Report for the year ended 31 March 2024.
Authority to Allot Shares
11. THAT in substitution for all existing authorities the Directors be and are hereby generally and unconditionally authorised in accordance with section 551 of the Companies Act 2006 (the “Act”) to exercise all powers of the Company to allot relevant securities (within the meaning of section 551 of the Act) up to a maximum aggregate nominal amount equal to 10% of the issued share capital of the Company at 5 June 2024 (or, if changed, the number representing 10% of the issued share capital of the Company at the date at which this resolution is passed), provided that this authority shall expire at the conclusion of the Annual General Meeting of the Company to be held in 2025 or 15 months from the date of passing this resolution, whichever is the earlier, unless previously revoked, varied or renewed, by the Company in General Meeting and provided that the Company shall be entitled to make, prior to the expiry of such authority, an offer or agreement which would or might require relevant securities to be allotted after such expiry and the Directors may allot relevant securities pursuant to such offer or agreement as if the authority conferred hereby had not expired.
Special Resolutions
To consider and, if thought fit, pass the following resolutions which will be proposed as special resolutions:
Disapplication of Pre-Emption Rights
12. THAT in substitution for all existing powers (and in addition to any power conferred on them by resolution 13 set out in the notice convening the Annual General Meeting at which this resolution is proposed (“Notice of Annual General Meeting”)) the Directors be and are hereby generally empowered pursuant to Section 570 of the Companies Act 2006 (the “Act”) to allot equity securities (within the meaning of Section 560 of the Act) for cash pursuant to the authority conferred on them by resolution 11 set out in the Notice of Annual General Meeting or otherwise as if Section 561(1) of the Act did not apply to any such allotment:
(a) pursuant to an offer of equity securities open for acceptance for a period fixed by the Directors where the equity securities respectively attributable to the interests of holders of shares in the capital of the Company (“Shares”) are proportionate (as nearly as may be) to the respective numbers of Shares held by them but subject to such exclusions or other arrangements in connection with the issue as the Directors may consider necessary, appropriate or expedient to deal with equity securities representing fractional entitlements or to deal with legal or practical problems arising in any overseas territory, the requirements of any regulatory body or stock exchange, or any other matter whatsoever;
(b) provided that (otherwise than pursuant to sub-paragraph (a) above) this power shall be limited to the allotment of equity securities up to an aggregate nominal value equal to 10% of the issued share capital of the Company at 5 June 2024 (or, if changed, the number representing 10% of the issued share capital of the Company at the date at which this resolution is passed) and provided further that (i) the number of equity securities to which this power applies shall be reduced from time to time by the number of treasury shares which are sold pursuant to any power conferred on the Directors by resolution 13 set out in the Notice of Annual General Meeting and (ii) no allotment of equity securities shall be made under this power which would result in Shares being issued at a price which is less than the net asset value per Share as at the latest practicable date before such allotment of equity securities as determined by the Directors in their reasonable discretion; and
such power shall expire at the conclusion of the next Annual General Meeting of the Company after the passing of this resolution or 15 months from the date of passing this resolution, whichever is earlier, unless previously revoked, varied or renewed by the Company in General Meeting and provided that the Company shall be entitled to make, prior to the expiry of such authority, an offer or agreement which would or might otherwise require equity securities to be allotted after such expiry and the Directors may allot equity securities pursuant to such offer or agreement as if the power conferred hereby had not expired.
13. THAT in substitution for all existing powers (and in addition to any power conferred on them by resolution 12 set out in the Notice of Annual General Meeting) the Directors be and are hereby generally empowered pursuant to Section 570 of the Companies Act 2006 (the “Act”) to sell relevant shares (within the meaning of Section 560 of the Act) if, immediately before the sale, such shares are held by the Company as treasury shares (as defined in Section 724 of the Act (“treasury shares”)), for cash as if Section 561(1) of the Act did not apply to any such sale provided that:
(a) this power shall be limited to the sale of relevant shares having an aggregate nominal value equal to 10% of the issued share capital of the Company at 5 June 2024 (or, if changed, the number representing 10% of the issued share capital of the Company at the date at which this resolution is passed) and provided further that the number of relevant shares to which power applies shall be reduced from time to time by the number of Shares which are allotted for cash as if Section 561(1) of the Act did not apply pursuant to the power conferred on the Directors by resolution 15 set out in the Notice of Annual General Meeting,
and such power shall expire at the conclusion of the next Annual General Meeting of the Company after the passing of this resolution or 15 months from the date of passing this resolution, whichever is earlier, unless previously revoked, varied or renewed by the Company in General Meeting and provided that the Company shall be entitled to make, prior to the expiry of such authority, an offer or agreement which would or might otherwise require treasury shares to be sold after such expiry and the Directors may sell treasury shares pursuant to such offer or agreement as if the power conferred hereby had not expired.
Authority to Repurchase Ordinary Shares
14. THAT the Company be and is hereby generally and unconditionally authorised in accordance with section 701 of the Companies Act 2006 (the “Act”) to make one or more market purchases (within the meaning of section 693 of the Act) of ordinary shares in the capital of the Company (“Shares”) (either for retention as treasury shares for future reissue, resale, transfer or cancellation), provided that:
(a) the maximum aggregate number of Shares authorised to be purchased shall be that number of shares which is equal to 14.99% of the issued share capital of the Company as of the value of the date of the passing of this resolution;
(b) the minimum price (exclusive of expenses) which may be paid for a Share is 2.5 pence;
(c)
the maximum price (exclusive of expenses) which may be paid for a Share is an amount equal to the greater of (i) 105% of the average of the middle market quotations for a Share as derived from the Daily Official List of the London Stock Exchange for the five business days immediately preceding the day on which that Share is purchased and (ii) the higher of the price of the last independent trade and the highest then current independent bid on the London Stock Exchange as stipulated in the technical standards referred to in Article 5(6) of the Market Abuse Regulation (EU) No. 596/2014 (which forms part of
(d) the authority hereby conferred shall expire at the conclusion of the Annual General Meeting of the Company to be held in 2025 or, if earlier, on the expiry of 15 months from the date of the passing of this resolution unless such authority is renewed prior to such time; and
(e) the Company may make a contract to purchase Shares under this authority before the expiry of such authority which will or may be executed wholly or partly after the expiration of such authority, and may make a purchase of Shares in pursuance of any such contract.
General Meetings
15. THAT the Directors be authorised to call general meetings (other than the Annual General Meeting of the Company) on not less than 14 clear days’ notice, such authority to expire on the conclusion of the next Annual General Meeting of the Company, or, if earlier, on the expiry 15 months from the date of the passing of the resolution.
Ordinary Resolution
To consider and, if thought fit, pass the following resolution which will be proposed as an ordinary resolution:
Continuance of the Company
16. To approve the continuance of the Company as an investment trust for a further period of five years.
By order of the Board Registered Office: OneWood Street London EC2V 7WSFrostrow Capital LLP Company Secretary 6 June 2024
NOTES
1. Members are entitled to appoint a proxy to exercise all or any of their rights to attend and to speak and vote on their behalf at the meeting. A shareholder may appoint more than one proxy in relation to the meeting provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that shareholder. A proxy need not be a shareholder of the Company.
2. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolutions. If no voting indication is given, a proxy may vote or abstain from voting at his/her discretion. A proxy may vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting.
3.
Hard copy forms of proxy have not been included with this notice. Members can vote by: logging onto www.signalshares.com and following instructions; requesting a hard copy form of proxy directly from the registrars,
4. In the case of a member which is a company, the instrument appointing a proxy must be executed under its seal or signed on its behalf by a duly authorised officer or attorney or other person authorised to sign. Any power of attorney or other authority under which the instrument is signed (or a certified copy of it) must be included with the instrument.
5. The return of a completed proxy form, other such instrument or any CREST Proxy Instruction (as described below) will not prevent a shareholder attending the meeting and voting in person if he/she wishes to do so.
6.
Any person to whom this notice is sent
7. The statement of the rights of shareholders in relation to the appointment of proxies in paragraphs 1 and 3 above does not apply to Nominated Persons. The rights described in these paragraphs can only be exercised by shareholders of the Company.
8. Pursuant to regulation 41 of the Uncertificated Securities Regulations 2001, only shareholders registered on the register of members of the Company (the “Register of Members”) at the close of business on Monday, 8 July 2024 (or, in the event of any adjournment, on the date which is two days before the time of the adjourned meeting) will be entitled to attend and vote or be represented at the meeting in respect of shares registered in their name at that time. Changes to the Register of Members after that time will be disregarded in determining the rights of any person to attend and vote at the meeting.
9. As at 5 June 2024 (being the last business day prior to the publication of this notice) the Company’s issued share capital consists of 601,665,200 ordinary shares, carrying one vote each. The Company holds 66,400,737 shares in treasury. Therefore, the total voting rights in the Company as at 5 June 2024 are 535,264,463.
10.
CREST members
11.
In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a “CREST Proxy Instruction”) must be properly authenticated in accordance with the specifications of Euroclear
12. CREST members and, where applicable, their CREST sponsors, or voting service providers should note that CRESTCo does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed a voting service provider, to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
13. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
14. If you are an institutional investor you may also be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by 1.00pm on 8 July 2024 in order to be considered valid or, in the event of any adjournment, close of business on the date which is two working days before the time of the adjourned meeting. Before you can appoint a proxy via this process you will need to have agreed to Proxymity’s associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy. An electronic proxy appointment via the Proxymity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your proxy vote.
15. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Register of Members in respect of the joint holding (the first named being the most senior).
16.
Members
17.
Members
18. If a member submits more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.
19.
In order to revoke a proxy instruction, members will need to inform the Company. Members should send a signed hard copy notice clearly stating their intention to revoke a proxy appointment to
EXPLANATORY NOTES TO THE RESOLUTIONS
Resolution 1 – To receive and adopt the Annual Report and Accounts
The Annual Report and Accounts for the year ended 31 March 2024 will be presented to the Annual General Meeting (“AGM”). These accounts accompany this Notice of Meeting.
Resolution 2 – To approve a Final Dividend
The rationale for the payment of a final dividend is set out in the Statement from the Chair and the Report of the Directors.
Resolution 3 – Approval of the Company’s Dividend Policy
Resolution 3 seeks shareholder approval of the Company’s dividend policy.
Resolutions 4 to 8 – Re-election of Directors
Resolutions 4 to 8 deal with the re-election of each Director.
The Board has confirmed, following a performance review, that the Directors standing for re-election and election continue to perform effectively.
Resolution 9 – Re-appointment of Auditors and the determination of their remuneration
Resolution 9 relates to the re-appointment of
Resolution 10 – Directors’ Remuneration Report
The Directors’ Remuneration Report is set out in full within the governance section of the annual report.
Resolutions 11, 12 and 13 – Issue of Shares
Ordinary Resolution 11 in the Notice of AGM will renew the authority to allot the unissued share capital up to an aggregate nominal amount equal to 10% of the aggregate nominal amount of the Company’s issued share capital on 5 June 2024, being the nearest practicable date prior to the signing of this Report (or if changed, the number representing 10% of the issued share capital of the Company at the date at which the resolution is passed). Such authority will expire on the date of the next AGM or after a period of 15 months from the date of the passing of the resolution, whichever is earlier. This means that the authority will have to be renewed at the next AGM.
When shares are to be allotted for cash, Section 551 of the Companies Act 2006 (the “Act”) provides that existing shareholders have pre-emption rights and that the new shares must be offered first to such shareholders in proportion to their existing holding of shares. However, shareholders can, by special resolution, authorise the Directors to allot shares otherwise than by a pro rata issue to existing shareholders. Special Resolution 12 will, if passed, give the Directors power to allot for cash equity securities up to an aggregate nominal amount equal to 10% of the Company’s share capital on 5 June 2024 (or if changed, the number representing 10% of the issued share capital of the Company at the date at which the resolution is passed), as if Section 551 of the Act does not apply. This is the same nominal amount of share capital which the Directors are seeking the authority to allot pursuant to Resolution 13. This authority will also expire on the date of the next Annual General Meeting or after a period of 15 months, whichever is earlier. This authority will not be used in connection with a rights issue by the Company.
Under the Companies (Acquisition of Own Shares) (Treasury Shares) Regulations 2003 (as amended) (the “Treasury Share Regulations”) the Company is permitted to buyback and hold shares in treasury and then sell them at a later date for cash, rather than cancelling them. The Treasury Share Regulations require such sale to be on a pre-emptive, pro rata , basis to existing shareholders unless shareholders agree by special resolution to disapply such pre-emption rights. Accordingly, in addition to giving the Directors power to allot unissued share capital on a non pre-emptive basis pursuant to Resolution 12, Resolution 13, if passed, will give the Directors authority to sell shares held in treasury on a non pre - emptive basis. No dividends may be paid on any shares held in treasury and no voting rights will attach to such shares. The benefit of the ability to hold treasury shares is that such shares may be resold. This should give the Company greater flexibility in managing its share capital, and improve liquidity in its shares. It is the intention of the Board that any re-sale of treasury shares would only take place at a premium to the cum income net asset value per share. It is also the intention of the Board that sales from treasury would only take place when the Board believes that to do so would assist in the provision of liquidity to the market. The number of treasury shares which may be sold pursuant to this authority is limited to an aggregate nominal amount equal to 10% of the Company’s share capital on 5 June 2024 (or if changed, the number representing 10% of the issued share capital of the Company at the date at which the resolution is passed) (reduced by any equity securities allotted for cash on a non-pro rata basis pursuant to Resolution 12, as described above). This authority will also expire on the date of the next Annual General Meeting or after a period of 15 months, whichever is earlier.
The Directors intend to use the authority given by Resolutions 11, 12 and 13 to allot shares and disapply pre-emption rights only in circumstances where this will be clearly beneficial to shareholders as a whole. The issue proceeds would be available for investment in line with the Company’s investment policy. No issue of shares will be made which would effectively alter the control of the Company without the prior approval of shareholders in general meeting.
New Shares will only be issued at a premium to the Company’s cum income net asset value per share at the time of issue.
Resolution 14 – Share Repurchases
The Directors wish to renew the authority given by shareholders at the previous AGM. The principal aim of a share buyback facility is to enhance shareholder value by acquiring shares at a discount to net asset value, as and when the Directors consider this to be appropriate. The purchase of Shares, when they are trading at a discount to net asset value per share should result in an increase in the net asset value per share for the remaining shareholders. This authority, if conferred, will only be exercised if to do so would result in an increase in the net asset value per share for the remaining shareholders and if it is in the best interests of shareholders generally. Any purchase of shares will be made within guidelines established from time to time by the Board. It is proposed to seek shareholder authority to renew this facility for another year at the AGM.
Under the current Listing Rules, the maximum price that may be paid on the exercise of this authority must not exceed the higher of (i) 105% of the average of the middle market quotations for the shares over the five business days immediately preceding the date of purchase and (ii) the higher of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out. The minimum price which may be paid is 2.5p per Share. Existing shares which are purchased under this authority will either be cancelled or held as Treasury Shares.
Special Resolution 14 in the Notice of AGM will renew the authority to purchase in the market a maximum of 14.99% of the issued share capital of the Company as at the date of the passing of the resolution, 14.99% of the issued share capital of the Company as changed by that resolution. Such authority will expire on the date of the next AGM or after a period of 15 months from the date of passing of the resolution, whichever is earlier. This means in effect that the authority will have to be renewed at the next AGM or earlier if the authority has been exhausted.
Resolution 15 – General Meetings
Special Resolution 15 seeks shareholder approval for the Company to hold General Meetings (other than the AGM) at 14 clear days’ notice. The Board confirms that the shorter notice period would only be used where it was merited by the purpose of the meeting.
Resolution 16 – Continuance of the Company as an investment trust. Ordinary Resolution 16 seeks shareholder approval for the Company to continue as an investment trust for a further period of five years.
Recommendation
The Board considers that the resolutions relating to the above items are in the best interests of shareholders as a whole. Accordingly, the Board unanimously recommends to the shareholders that they vote in favour of the above resolutions to be proposed at the forthcoming AGM as the Directors intend to do in respect of their own beneficial holdings totalling 548,017 shares.
-ENDS-
Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.
For further information please contact
For and on behalf of
Company Secretary
0203 008 4913